PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

International Liver Congress™ 2022

22-26 June, 2022 London

N. Poster

Poster title

Applicant name

Status


FL-001	Chemokine receptor (CCR2 and CCR8) peptide antagonist asa promising treatment for non-alcoholic steatohepatitis (NASH)	E. Geervliet	Received

SAT-001	The DNA damage response is involved in the metabolic dysregulation of MAFLD patients via inefficient fatty acid oxidation	Beatriz Gomez Santos	Received

THU-001	Heavy alcohol intake along with ALDH2 polymorphism increases the risk of hepatocellular carcinoma and mortality in hepatitis B virus-related cirrhosis	Chih-Wen Lin	Received

FRI-001	Obeticholic acid exacerbates the liver fibrosis of bile duct ligation model by inducing the liver expression of osteopontin	Jie Wang	Received

FRI-002	A report on the Australian Drug Induced Liver Injury Network: AusDILIN	Amanda Nicoll	Received

THU-002	Biomarkers for prediction of alcohol-related liver cirrhosis in the Swedish general population	Gustav Jakobsson	Received

SAT-002	Hepatic miR-144 drives fumarase activity preventing NRF2 activation during obesity	Valerio Azzimato	Received

FL-002	Role of PDIA4 in Alpha 1-Antitrypsin Deficiency	Marion Bouchecareilh	Received

FL-003	EVALUATION OF THE ROLE OF HNF1B DEFICIENCY IN CHOLESTATIC LIVER DISEASE	M. Pinon	Received

THU-003	A history of bariatric surgery is independently associated with a younger age at onset of severe alcoholic hepatitis	Lukas Van Melkebeke	Received

FRI-003	Incidence, phenotype and prognostic relevance of COVID-19-related liver injury across different age strata	Lukas Hartl	Received

SAT-003	TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD	Heike Bantel	Received

THU-004	Cyclophilin inhibitor CRV431 as a potential therapy for alcohol-related liver disease	Elena Palma	Received

FL-004	The stellate cell clock in liver fibrosis	M. Johanns	Received

SAT-004	Obesity alters the partitioning of glycerol metabolism pathways in NAFLD	Jack Carruthers	Received

FRI-004	Two different types of COVID-19 vaccines and serial liver biochemistries	Grace Wong	Received

FL-005	Overcoming resistance to immune checkpoint inhibitors in HCC	Ugne Balaseviciute	Received

THU-005	UK national service evaluation of transplant assessments for patients with alcohol related liver disease	Christopher Oldroyd	Received

SAT-005	Human induced pluripotent stem cell-derived mesenchymal stem cells ameliorates mitochondrial oxidative dysfunction in non-alcoholic fatty liver disease	Min Kyung Park	Received

FRI-005	Role of liver biopsy in management of immune checkpoint inhibitors hepatitis: a single-center retrospective study	Lucia Parlati	Received

FRI-006	Immune checkpoint inhibitors induced liver injury: an observational study	Lucy Meunier	Received

SAT-006	Skeletal muscle-derived myokine affects insulin sensitivity and lipogenesis in a human hepatocyte spheroid model	Jean-Baptiste Potier	Received

FL-006	Natural antibodies are required for cell debrisclearance and liver repair during necrotic liver injury	M. Mattos	Received

THU-006	Fibroblast growth factor 21 is the main alcohol responsive peptide hormone in humans and individuals with alcohol use disorder exihibit increased plasma concentrations after alcohol intake	Amalie Lanng	Received

SAT-007	Patient-derived liver organoids to reveal PNPLA3 I148M role in Non-Alcoholic Fatty Liver Disease	Elia Casirati	Received

THU-007	Tight junction damage and increased gut permeability in alcohol-related liver disease may be mediated by gut proteases	Charlotte Skinner	Received

FRI-007	Liver toxicities of immune checkpoints inhibitors for cancer: a multicenter retrospective study	Lucia Parlati	Received

THU-008	Incident acute kidney injury in severe alcohol-related hepatitis is strongly associated with mortality and can be predicted using micro-RNAs and markers of systemic inflammation	Luke Tyson	Received

FRI-008	Acute severe presentation of autoimmune hepatitis: a 20-year retrospective review of the United States	Thomas Enke	Received

SAT-008	Transcriptomic analysis confirms that PNPLA3 I148M variant is associated with impaired mitochondrial function and antioxidant response in 3D cultured human hepatic stellate cells and liver tissue of patients with NAFLD	Elisabetta Caon	Received

FRI-009	Single-cell metabolic profiling of primary human hepatocytes shows heterogenous responses to drug metabolism	Eva Sofía Sánchez Quant	Received

THU-009	The impact of addiction team integration into the management of patients transplanted for alcohol-related liver disease: results from a multicenter comparative study	Jules Daniel	Received

SAT-009	HTD1801 (berberbine ursodeoxycholate), a unique single molecule with multiple beneficial effects in metabolic and liver diseases	Kjersti Swearingen	Received

FRI-010	Management of severe, steroid-resistant and steroid-refractory hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy	Morven Cunningham	Received

SAT-010	Metabolic, biochemical, histopathological and transcriptomic effects of long-acting FGF21 analogue in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH	Malte Hasle Nielsen	Received

THU-010	Risk of fractures and subsequent mortality in alcohol-related cirrhosis: a nationwide population-based cohort study	Axel Wester	Received

SAT-011	NAFLD-induced encephalopathy is associated with low-grade brain tissue hypoxia and inflammation, as well as cerebrovascular, glial, metabolic and behavioural alterations	Anna Hadjihambi	Received

THU-011	Use of statins among patients with cirrhosis due to alcohol-related liver disease - a danish nationwide cohort study	Anna Marine Slling Ramsing	Received

FRI-011	Activation marker CD69 differentiates non-alcoholic steatohepatitis from drug-induced liver injury	Alberto Garcia Garcia	Received

FRI-012	Natural antibodies are required for necrotic cell debris clearance and liver repair during necrotic liver injury	Matheus Mattos	Received

THU-012	Antibody response to gut microbiome bacteria in human alcoholic liver disease	Antonella Putignano	Received

SAT-013	Targeted metabolomics reveals alterations in one-carbon metabolism in NAFLD patients	Mikkel Werge	Received

FRI-013	Human paracetamol hepatotoxicity is mitigated by the gut-liver axis in vitro	Martin Vandeputte	Received

THU-013	Socio-economic factors and healthcare setting are independently associated with medium and long-term outcomes from alcohol-related hepatitis	Joshua Lambert	Received

THU-014	Sex-related differences in outcomes in alcohol-related cirrhosis following an episode of hepatic decompensation do not explain subsequent management inequalities	Aaminah Mohammed	Received

FRI-015	Ten-year single center experience in hepatotoxicity due to mushroom poisoning	Ozan Sarikaya	Received

SAT-015	Deletion of ATR in hepatocytes improves NAFLD features by increasing mitochondrial function	Maeva Saroul	Received

THU-015	Influence of comorbidities and lifestyle factors on health-related quality of life in alcohol-related liver disease: a population-based survey	Karen Dombestein Elde	Received

SAT-016	The AXL inhibitor bemcentinib reduces inflammation and fibrosis by inducing a dynamic change in macrophages and CD8T cells subsets during experimental NASH	Sturla M. Groendal	Received

THU-016	Patient and system-level factors underline offering and acceptance of alcohol use disorder therapy in veterans with cirrhosis	Jasmohan S Bajaj	Received

FRI-017	The association between chronic Colchicine use and incident decompensated cirrhosis	Michal Carmiel	Received

SAT-017	Human Liver Organoids with myeloid lineages model the multi-cellular crosstalk in Non-Alcoholic Steatohepatitis	Milad Rezvani	Received

THU-017	24-Norursodeoxycholic acid ameliorates experimental alcoholic liver disease in both preventive and therapeutic settings	Christoph Grander	Received

FRI-018	Inhibition of C-C motif chemokine receptor 2 (CCR2) using a novel in silico designed peptide attenuates macrophage migration in vitro and intrahepatic monocyte recruitment in vivo	Eline Geervliet	Received

THU-018	Impact of sex and recurrence in the prognosis of alcoholic hepatitis	Jordi Gratacós-Ginès	Received

SAT-019	Increased liver content of omega-3-derived lipid mediators associates with enhanced mitochondrial oxidative phosphorylation, fatty acid oxidation and metabolic efficiency	Cristina López-Vicario	Received

FRI-019	Murine intrahepatic regulatory t cells modulate acute liver inflammation by promoting a protective and restorative microenvironment	Ada Kurt	Received

THU-019	Hepatocyte-derived biomarkers concentrations predict liver-related events within 2 years in patients with Child-Pugh class A alcohol-related cirrhosis	LAURE ELKRIEF	Received

SAT-020	Factors associated with increased gut permeability and severity of liver disease in diabetic patients with NAFLD	Roberta Forlano	Received

FRI-020	Place of steroids and prognosis factors for grade =3 immune-checkpoint inhibitors induced hepatitis: a 6-year prospective study	Eleonora De Martin	Received

THU-020	Dynamic multiomics analysis characterizes circulating molecular determinants associated with poor outcome in patients with severe alcoholic hepatitis	Jaswinder Maras	Received

THU-021	Alcohol-induced changes of inflammatory markers in hepatic and systemic venous blood in early alcohol-related and non-alcoholic fatty liver disease	Evelina Stankevic	Received

FRI-021	The role of macrophage ETS Proto-oncogene 2 in acute-on-chronic liver failure	Lulu He	Received

SAT-021	Increased burden of inherited IRF3 rare genetic variants in Europeans with severe Non-alcoholic fatty liver diease	Alessandro Cherubini	Received

SAT-022	Sex-dependent hepatoprotective role of IL-22 in NAFLD-related fibrosis	Mohamed Noureldin Hassan Ali Abdelanbi	Received

FRI-022	Novel strategies required to further improve outcomes in Acute Liver Failure.	William Bernal	Received

THU-022	New treatment for alcohol-related liver disease: combinations of efficacy and treatment cost required for cost-effectiveness	Davit Khlghatyan	Received

SAT-023	Identification of novel targets in adipose tissue involved in non-alcoholic fatty liver disease progression	Jose M Arbones-Mainar	Received

FRI-023	Human liver biopsies from people with hemophilia A who received factor VIII gene transfer with valoctocogene roxaparvovec (AAV5-hFVIII-SQ) show unremarkable histopathology and reveal interindividual variability in transgene production	Sylvia Fong	Received

THU-023	Active alcohol misuse is linked with lower short-chain fatty acid producing microbiota in a matched study of 450 patients with cirrhosis	Jasmohan S Bajaj	Received

SAT-024	Isoleucine and valine correct hepatic lipid processing, reduce liver steatosis and suppress inflammation in obese mice with manifest NASH	Eveline Gart	Received

FRI-024	Liver toxicity associated to novel cyclin-dependent kinase inhibitor ribociclib in a cohort of advanced breast cancer patients	Miki Scaravaglio	Received

THU-024	Infections are common in patients with early alcohol-related liver disease and increases the risk of death	Stine Johansen	Received

THU-025	Abstinence is associated with better outcome in patients with hepatocellular carcinoma	Astrid Marot	Received

SAT-025	Butyrate protects against diet-induced NASH and liver fibrosis and suppresses specific non-canonical TGFB signaling pathways in human hepatic stellate cells	Eveline Gart	Received

FRI-025	Exogenous fibroblast growth factor 7 improved hepatocyte regeneration and ameliorated CCl4-induced acute liver injury in vivo	Eline Geervliet	Received

SAT-026	Experimental non-alcoholic fatty liver disease causes regional liver functional deficits while total metabolic liver function is preserved	Peter Lykke Eriksen	Received

THU-026	In severe alcohol-related hepatitis, hepatocyte ballooning correlates with expression of p16 and components of a secretory phenotype that has been associated with cellular senescence	Nikhil Vergis	Received

FRI-026	Three COVID-19 medications - remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir - and serial liver biochemistries in 22,456 subjects	Grace Wong	Received

THU-027	Targeting cyclin M4 as a new therapeutical approach to treat alcoholic liver disease	Irene Gonzalez Recio	Received

SAT-027	Hepatic lipid fingerprint reveals sex-dependent lipid droplet composition in metabolic associated fatty liver disease	Elisabet Rodríguez Tomàs	Received

FRI-027	TRENDS IN LIVER TRANSPLANTATION FOR ACUTE LIVER FAILURE. A SPANISH MULTICENTER STUDY	Isabel Conde Amiel	Received

SAT-028	Lipidomics and proteomics reveal mitochondrial dysfunction in liver and visceral adipose tissue from patients with nonalcoholic steatohepatitis	Helena Castañé	Received

THU-028	Hepatic transcriptional signature of alcohol on genes involved in canonical retinoid metabolism	Steven Trasino	Received

FRI-028	Hepatobiliary disease after bone marrow transplant	Maria Dezan	Received

THU-029	COVID-19 pandemic impact on alcoholic hepatitis healthcare utilisation	Leya Nedumannil	Received

SAT-029	Targeting liver glutaminase 1 modulates hepatic ammonia in experimental Non-Alcoholic Steatohepatitis	Maria Mercado-Gómez	Received

FRI-029	FOXA2 prevents hyperbilirubinemia through maintaining apical MRP2 expression in acute liver failure	Sai Wang	Received

SAT-030	Clinical relevance of an animal model of nonalcoholic steatohepatitis (NASH) and digital pathology with artificial intelligence (DP-AI) analyses of hepatic fibrosis	Deming Xu	Received

FRI-030	Machine learning encoding of liver biopsy images enables prediction of molecular measurements in a NASH F3/F4 fibrosis clinical cohort	Michael D. Bereket	Received

SAT-031	Small changes in the metabolism of bile acids by the gut microbiota are associated to NASH pathogenesis	Justine Gillard	Received

THU-031	Untargeted lipidomics unveils a specific plasma signature of severe alcoholic hepatitis	Florent Artru	Received

FRI-031	Validation of AI-assisted method of liver fat measurement in adults with type 2 diabetes	Tim St Pierre	Received

SAT-032	Unravelling the landscape of adipose tissue macrophages in human non-alcoholic fatty liver disease	Markus Boesch	Received

THU-032	Toll-like receptor 2 activation in monocytes of alcohol use disorder patients contributes to systemic inflammation and alcohol-associated liver disease	Luca Maccioni	Received

FRI-032	Identifying advanced liver disease in asymptomatic patients in primary care: an evaluation of patient outcomes 24 months after implementing a primary care liver pathway and community liver service	Tina Reinson	Received

THU-033	Improving NIAAA criteria for the diagnosis of alcoholic hepatitis, role of systemic inflammation	EMMA Avitabile	Received

SAT-033	Atorvastatin attenuates diet-induced non-alcoholic steatohepatitis in ApoE3-Leiden mice by reducing hepatic inflammation	José A. Inia	Received

FRI-033	Predictive survival-time modelling of Non-Alcoholic Steatohepatitis (NASH) fast progressors using real-world evidence	Nils Svangrd	Received

FRI-034	Online education significantly improved gastroenterologists knowledge of the diagnostic and monitoring techniques used in liver fibrosis	James White	Received

SAT-034	Carnitine signature in liver corretales with nonalcoholic fatty liver disease progression	Andrea Jiménez Franco	Received

THU-034	Alcohol associated hepatitis in Latin America: results from the AH-LATIN study	Jorge Arnold	Received

SAT-035	Type 2 diabetes and religious fasting: effects on metabolism and liver steatosis	Svenja Sydor	Received

FRI-035	Health outcomes and risk assessment in chronic liver disease (HERALD): a large Swedish research platform	Emilie Toresson Grip	Received

THU-035	Prophylaxis of withdrawal syndrome decreases mortality in patients with alcohol-associated hepatitis	David Marti-Aguado	Received

THU-036	The use of pharmacotherapy in the treatment of alcohol use disorder	Kathryn Allen	Received

SAT-036	The I48M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in non-alcoholic fatty liver disease (NAFLD) patients gains value	erika paolini	Received

FRI-036	Impact of alcohol use on the diagnostic performance of serum-based indices for fatty liver disease	Oscar Danielsson	Received

FRI-037	Liver stiffness on magnetic resonance elastography and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants	Veeral Ajmera	Received

SAT-037	The co-presence of PNPLA3, MBOAT7 and TM6SF2 loss-of-functions impairs mitochondrial morphology and number in severe NAFLD patients	Miriam Longo	Received

THU-037	Application of machine learning algorithms to classify steatohepatitis on liver biopsy	Resham Ramkissoon	Received

SAT-038	The association of spleen volume with sex, age, type 2-diabetes, and non-alcoholic fatty liver disease - initial results from more than 35,000 UK Biobank participants	Lars Johansson	Received

FRI-038	Utilising features of metabolic syndrome to cost-effectively improve metabolic dysfunction-associated fatty liver disease diagnosis rates	Cassandra Baiano	Received

SAT-039	Targeting adipose tissue macrophages ameliorates hepatic injury in a murine model of NAFLD	Celia Martínez Sánchez	Received

FRI-039	Non-invasive assessment of type VII collagen degradation is related to NAFLD activity but not fibrosis stage	Mette Juul Nielsen	Received

THU-039	Alcoholic foamy degeneration: a unique variant of ALD that shows a characteristic pattern of gene expression with upregulation of lipid metabolism and mitochondrial genes and downregulation of fibrosis genes	Jordi Gratacós-Ginès	Received

SAT-040	Multiplex immunostaining and transcriptomic profiling identify novel immune cell markers for non-alcoholic steatohepatitis and primary sclerosing cholangitis	Adrien Guillot	Received

FRI-040	Reliability of histologic disease activity measures in non-alcoholic fatty liver disease (NAFLD) and development of an expanded NAFLD activity score	Rohit Loomba	Received

THU-040	Loss of solute carrier family 38 member 4 (SLC38A4) as a driver for the pathogenesis of severe alcoholic hepatitis	Nchimunya Nelisa Tebeka	Received

FRI-041	Evaluating future risk of NAFLD fibrosis in adolescents: prediction and decision curve analysis	Kushala Abeysekera	Received

THU-041	Refining the natural history of alcohol related liver disease: a competing risk analysis	Richard Parker	Received

SAT-041	Phospholipid fingerprints reveal sex differences in the adipose tissue phospholipid composition from morbidly obese patients	Gerard Baiges	Received

FRI-042	Quantification of hepatic steatosis in patients with non-alcoholic fatty liver disease: comparison of sound speed, attenuation coefficient and continuous CAP measurements with MRI-PDFF	Rémi COLLIN	Received

SAT-042	Ubiquitination of GSDMD regulated by NEDD4 is involved in hepatocyte pyroptosis of nonalcoholic steatohepatitis	Rui Jin	Received

THU-042	Potential biomarkers for differentiating alcoholic hepatitis from decompensated cirrhosis by serum metabolomic analysis	Adelina Horhat	Received

SAT-043	Unraveling the transcriptional dynamics of NASH pathogenesis affecting atherosclerosis development	Geurt Stokman	Received

FRI-043	Community NAFLD screening programme in patients with type 2 diabetes mellitus indicates high burden of undiagnosed liver disease	Emma McCormick	Received

SAT-044	Repeated weight cycling in obese mice improves hepatic inflammation	Geurt Stokman	Received

THU-044	Trends of alcohol-related liver disease hospitalisation during the COVID-19 pandemic	Richard Goodheart	Received

FRI-044	Non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus in Greenland	Rasmus Hvidbjerg Gantzel	Received

THU-045	Increased hospital admissions for alcohol-associated hepatitis during the COVID-19 pandemic in Alberta, Canada: A retrospective cohort study	Alexandra Frolkis	Received

FRI-045	A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640: results from the FASCINATE-1 study	Rohit Loomba	Received

SAT-045	The functional roles of BMP10 in the pathogenesis of nonalcoholic fatty liver disease	Wenjun Zhang	Received

THU-046	The lysosomal enzyme cathepsin D as a new marker for alcoholic liver disease	Ronit Shiri-Sverdlov	Received

FRI-046	Enchanced Liver Fibrosis test in predicting severe liver-related outcomes in the general population	Kustaa Saarinen	Received

SAT-046	Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with severe hepatic impairment	Liz Artwick	Received

SAT-047	Amino acid glycine suppresses steatohepatitis and tumorigenesis in hepatocyte-specific phosphatase and tensin homolog knockout mice	Kazuyoshi Kon	Received

THU-047	Ductular bilirubinostasis is a diagnostic biomarker for acute-on-chronic liver failure: results from a well-defined cohort of patients with alcoholic steatohepatitis	Annelotte Broekhoven	Received

FRI-047	Radiowater perfusion PET of the liver, and its value as a biomarker to discriminate between NAFLD and NASH, and activity and fibrosis grade	Olof Eriksson	Received

SAT-048	Advanced quantitative phenotypic fibrosis and steatosis scoring is more superior to histology-based conventional staging in NASH animal models	Li Chen	Received

THU-048	The most recent and in-depth meta-analytic assessment of the global epidemiology of Nonalcoholic fatty liver disease (NAFLD)	Carey Escheik	Received

FRI-048	The combination of the ELF and FIB-4 scores have high predictive performance for significant fibrosis in patients with NAFLD	Carey Escheik	Received

THU-049	Comorbidities and Malignancy among NAFLD patients compared to general population	Naim Ab-Freha	Received

SAT-049	Chemical suppression of adipose triglyceride lipase improves nonalcoholic steatohepatitis in a diabetic and hyperlipidemic mouse model	Emmanuel Dauda Dixon	Received

FRI-049	Association of the biological age and the level of global deoxyribonucleic acid methylation with metabolic parameters in patients with non-alcoholic fatty liver disease	Anastasiia Radchenko	Received

SAT-050	Methionine adenosyltransferase 1a antisense oligonucleotides induce the fibroblast growth factor 21-driven recovery from obesity and associated hepatoesteatosis	Xabier Buque	Received

FRI-050	LEARN algorithm: a novel option for predicting non-alcoholic steatohepatitis	Gang Li	Received

THU-050	The prevalence of non-alcoholic fatty liver disease in the United Kingdom: a systematic review and meta-analysis	Yusef Alenezi	Received

THU-051	Health-related quality of life is impaired in people living with HIV and hepatic steatosis	Maurice Michel	Received

FRI-051	Head to head comparison between MEFIB versus MAST for identification of high-risk patients with NAFLD	Beom Kyung Kim	Received

SAT-051	NLRP3 inflammasome dependent cell death in myeloid cells drives liver inflammation and fibrosis in murine steatohepatitis	Benedikt Kaufmann	Received

THU-052	Moderate alcohol consumption is associated with significant fibrosis progression in non-alcoholic fatty liver disease - a cohort study with over 17 years of follow-up	Julia Blomdahl	Received

SAT-052	The PNPLA3 I148M variant increases intrahepatic lipolysis and beta oxidation and decreases de novo lipogenesis and hepatic mitochondrial function in humans	Panu Luukkonen	Received

FRI-052	MRI assessment (cT1) with LiverMultiScan following VCTE improves the diagnostic yield for high-risk NASH	Cayden Beyer	Received

SAT-053	Two diseases, one model - assessing the suitability of FOZ mice to examine CVD in NAFLD	Sebastian Bott	Received

THU-053	Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: korean military population-based cross-sectional study	Jaejun Lee	Received

FRI-053	The PNPLA3 (rs738409) G/G-genotype is associated with presence of NASH and increased long-term risk of cirrhosis in NAFLD	Magnus Holmer	Received

FRI-054	Hepatic expression of secreted calcium-binding protein 2 by hepatic stellate cells is associated with human non-alcoholic fatty liver disease progression	Frederik Larsen	Received

THU-054	Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis	James Thomas	Received

SAT-055	The ubiquitin-like modifier FAT10 is upregulated during NASH and impairs PPAR-alpha activity	Ludivine Clavreul	Received

FRI-055	Clinicians perspectives on barriers and facilitators for the adoption of non-invasive liver tests: a mixed-method study	Yasaman Vali	Received

THU-055	Association of non-alcoholic fatty liver disease and fibrosis with incident dementia and cognitive function: the Rotterdam Study	Laurens Van Kleef	Received

FRI-056	Ectopic fat deposition in the liver and pancreas and the presence of excess visceral adipose tissue significantly increase hospitalisation risk following COVID-19	Tom Waddell	Received

THU-056	High meat consumption is prospectively associated with non alcoholic fatty liver disease and liver fibrosis markers	Dana Ivancovsky Wajcman	Received

SAT-056	TNF-alpha knockout mice are protected from diet-induced NAFLD in a model of non-obese NAFLD	Katharina Burger	Received

SAT-057	Low dose thyroid hormone improves hepatic mitochondrial fatty acid oxidation and rescues nonalcoholic fatty liver disease in mice	Raghu Ramanathan	Received

FRI-057	Genomic and metabolomic profiles and their correlations with preclinical signs of endothelial dysfunction measured by peripheral arterial tonometry in non-alcoholic fatty liver disease	Mario Masarone	Received

THU-057	Relevance of diabetes medication on recruitment criteria for clinical studies in patients with nonalcoholic fatty disease and type 2 diabetes mellitus	Johannes Wiegand	Received

SAT-058	Three-dimensional imaging of cleared human liver tissues reveals extensive fibrosis heterogeneity in non-alcoholic fatty liver disease	Buket Yigit	Received

THU-058	Comorbidity severity scores and cardiovascular comorbidities in patients with non-alcoholic steatohepatitis (NASH), with and without cirrhosis, in a real-world setting	Jeffrey Lazarus	Received

FRI-058	Determinants of liver stiffness measurements in patients with NAFLD - an individual patient data meta-analysis	Ferenc Mozes	Received

THU-059	NAFLD association with renal impairment in type 2 diabetes patients	Jesús Rivera-Esteban	Received

FRI-059	Knowledge of liver fibrosis stage among adults with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis improves adherence to life style changes	Jeffrey Lazarus	Received

SAT-060	Hepatic insulin resistance is the basis of bile acid dysmetabolism in non-alcoholic fatty liver disease	Sami Qadri	Received

FRI-060	The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH	Mazen Noureddin	Received

THU-060	The impact of liver fibrosis on the immune response to SARS-CoV-2 vaccination in metabolic associated fatty liver disease patients	Marta Freitas	Received

FRI-061	Independent determinants of CAP values in healthy individuals with dysmetabolism	Cristiana Bianco	Received

THU-061	Non-alcoholic steatohepatitis is also becoming a major liver transplant indication in Spain, a historically low risk area	Laura Martínez-Arenas	Received

SAT-061	Non-alcoholic fatty liver disease features a reduced reverse polyunsaturated fatty acid transport (free fatty acids/high-density lipoprotein) from the periphery to the liver	Gabriele Mocciaro	Received

THU-062	Total healthcare cost and characteristics associated with higher change in cost in patients with non-alcoholic steatohepatitis	Zobair Younossi	Received

FRI-062	Performance of liver-related clinical scores in the SAPHIR study	Lorenz Balcar	Received

SAT-063	FXR binding and transcription in the liver is signficantly altered in obese patients with NAFLD	Martin Wagner	Received

THU-063	Nonalcoholic fatty liver disease (NAFLD) / nonalcoholic steatohepatitis (NASH) is associated with worse outcomes in patients hospitalised for COVID-19: a real-world analysis of a large population from the premier healthcare database	Frank Tacke	Received

FRI-063	Correlations of 2D-Shear wave and transient elastography liver stiffness measurements in patients with non-alcoholic fatty liver disease	Dimitrios Karagiannakis	Received

THU-064	Estimating the prevalence of advanced fibrosis due to nonalcoholic fatty liver disease in the United States population	Naim Alkhouri	Received

FRI-064	Performance of the Enhanced Liver Fibrosis (ELF) test in real world practice versus clinical trials of non-alcoholic steatohepatitis	Carey Escheik	Received

SAT-064	Non-alcoholic fatty liver disease (NAFLD) progression to non-alcoholic steatohepatitis (NASH) and NASH-related hepatocellular carcinoma (HCC ) evolves following a differential activation of Endoplasmic Reticulum Stress responses	Alexander Nicholas Finnemore Capon Diaz	Received

FRI-065	Machine learning using simple non-invasive tests of fibrosis and B-mode ultrasound for the prediction of adverse liver-related outcomes in NAFLD	Heather Kosick	Received

SAT-065	MPEP, an mGlu5 receptor allosteric modulator, reduces hepatic steatosis in obese high-fat-diet mice	Laura Giuseppina Di Pasqua	Received

THU-065	Non-alcholic fatty liver disease associated liver fibrosis is linked with the severity of coronnary artery disease mediated by systemic inflammation	Xianbin Cai	Received

FRI-066	Incorporating a two-tiered liver fibrosis assessment into annual diabetes review in primary care - 3 year follow up study	Dina Mansour	Received

THU-066	Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease related cirrhossis: a meta-analysis of observational studies	Roberta Stupia	Received

SAT-066	Pro-inflammatory liver-homing T cells in peripheral blood, liver and adipose tissue in patients with NASH and changes in post-bariatric surgery samples	James Brindley	Received

THU-067	Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-nonalcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy	Federico Ravaioli	Received

FRI-067	New scoring system using MRI with AST for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis	Kento Imajo	Received

SAT-067	Therapeutic inhibition of complement component 5 does not reduce NASH progression but does attenuate atherosclerosis development in Ldlr-/-.Leiden mice	Florine Seidel	Received

FRI-068	Impact of artificial intelligence assistive tool on the histopathologic review of fibrosis in non-alcoholic steatohepatitis patients	Elaine Chng	Received

SAT-068	The overexpression of TM6SF2 and/or MBOAT7 wild-type genes re-establishes the mitochondrial dynamics in an in vitro NAFLD model.	erika paolini	Received

THU-068	Postprandial dysfunction in metabolic associated fatty liver disease (MAFLD)	Josephine Grandt	Received

SAT-069	CD1d knockdown promotes NAFL lipid synthesis by activating the IL6-JAK1-STAT3 signal pathway and reduces inflammatory factors in NASH by decreasing macrophage polarisation towards M1 and increasingn polarisation towards M2	Dandan Shan	Received

THU-069	Lean non-alcoholic fatty liver disease patients from the global NASH registry	Carey Escheik	Received

FRI-069	PRO-C3 based sequential algorithm can screen high-risk NASH and severe fibrosis in asian NAFLD population	Liang-Jie Tang	Received

SAT-070	The role of immune semaphorins in NAFLD - a pilot study	Ivana Knezevic Stromar	Received

FRI-070	Real-world use of the FIB-4 calculator in primary care workflows to screen for advanced non-alcoholic fatty liver disease in a large US health system	George Therapondos	Received

THU-070	Automated FIB-4 calculator and targeted provider education improved referral of at-risk fibrotic NAFLD patients	Cindy Piao	Received

THU-071	Long term outcomes of non-alcoholic fatty liver disease (NAFLD) and metabolic associated fatty liver disease (MAFLD)	Carey Escheik	Received

FRI-071	In silico identification and validation of plasma Ficolin-2 (FCN-2) as non-invasive biomarker of fibrosis in Non-alcoholic Fatty Liver Disease (NAFLD)	Noel Salvoza	Received

SAT-071	Machine learning-enabled continuous scoring of histologic features facilitates prediction of clinical disease progression in patients with non-alcoholic steatohepatitis	Janani Iyer	Received

THU-072	MARC1 and HSD17B13 variants have protective effects on liver injury in the obese: results from a prospective cohort of patients undergoing bariatric surgery	Marcin Krawczyk	Received

FRI-072	A lower cut-off of liver stiffness measurement (8/13) kPa performs better than Baveno 6 criteria for advanced chronic liver disease in patients with non-alcoholic fatty liver disease	Sagnik Biswas	Received

THU-073	The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease (NAFLD): data from national health and nutrition examination survey (NHANES) 2005-2018	Carey Escheik	Received

SAT-073	Validation of the ADAPT score for the diagnosis of clinically significant fibrosis in patients with nonalcoholic fatty liver disease (NAFLD)	Emily Wigginton	Received

FRI-073	High prevalence of multi-organ steatosis and fibroinflammation, identified by multi-parametric magnetic resonance imaging, in people with type 2 diabetes	Nicole Eichert	Received

SAT-074	Obeticholic acid reduces hepatic matrix metalloproteinase activity in a diet-induced ob/ob mouse model of NASH	Marta Cagna	Received

THU-074	Metabolic dysfunction-associated fatty liver disease increases cardiovascular risk regardless of classical risk factors	María Del Barrio Azaceta	Received

FRI-074	Plasma TREM2, a novel non-invasive biomarker for diagnosis of NASH in NAFLD patients with elevated liver stiffness	Charlotte Wernberg	Received

THU-075	Changes in hepatic fat fraction as assessed by MRI-PDFF are correlated with changes in markers of hepatic inflammation, disease activity and fibrosis in biopsy-proven non-cirrhotic NASH with fibrosis	Samuel Daniels	Received

SAT-075	Evaluation of semisynthetic high-fat diets in development of a 4-week mouse NASH model	Ozren Majstorovic	Received

FRI-075	Unbiased clustering of exhaled breath profiles in metabolic dysfunction-associated fatty liver disease identifies a patient phenotype at higher risk of disease progression	Rohit Sinha	Received

THU-076	The metabolic dysfunction-associated fatty liver disease definition, regardless of its clinical subclassification, identifies patients at high risk for liver disease progression	María Del Barrio Azaceta	Received

FRI-076	The pericellular basement of the hepatocytes is highly affected by bariatric surgery in obese patients with non-alcoholic fatty liver disease	Ida Lnsmann	Received

SAT-076	Tyrosinase mutations, a novel predisposing genetic factor for enhanced nonalcoholic steatohepatitis susceptibility	Kaushalya Kulathunga	Received

FRI-077	A re-appraisal of the diagnostic performance of ultrasonography for fatty liver disease	Chul-min Lee	Received

THU-077	Assessment of the prevalence of nonalcoholic fatty liver disease, its severity, and comorbidities in lean americans: national health and nutrition examination surveys (NHANES) with transient elastography assessment from 2017 to 2018	Emily Truong	Received

SAT-078	Recapitulating insulin resistance in a 3D human liver model for efficacy testing of drug candidates	Radina Kostadinova	Received

THU-078	Coagulation imbalance is associated with hepatic fibrosis and vascular complications in patients with type2 diabetes and NAFLD	Rosa Lombardi	Received

FRI-078	Cost utility analysis for screening for fibrotic NASH in the type 2 population from European countries	Mazen Noureddin	Received

FRI-079	Free Light Chains as a potential biomarker of inflammation and fibrosis in non-alcoholic steatohepatitis	Antonio Liguori	Received

SAT-079	Novel endosomal trafficking adaptor for the regulation of NAFLD to NASH progression	Karsten Motzler	Received

THU-079	Presence of two or more metabolic risks regardless of fatty liver is a risk factor for significant hepatic fibrosis	HUIYUL PARK	Received

THU-080	Pregnancy as a unique opportunity to identify NAFLD in women: a prospective assessment	Tatyana Kushner	Received

FRI-080	12-week very low calorie diet in NAFLD induces rapid improvements in biomarkers of necro-apoptosis and fibrogenesis of a magnitude comparable to those seen in phase 2 drug trials	Jadine Scragg	Received

SAT-080	Enzymatic activity dysfunction of the mitochondrial respiratory chain, in the full spectrum of the METABOLIC ASSOCIATED FATTY LIVER DISEASE	Alberto García Picazo	Received

FRI-081	Signature of circulating hepatic proteins detects fibrosing-steatohepatitis in progressive non-alcoholic fatty liver disease	Olivier Govaere	Received

SAT-081	Lipid-induced phenotypic differences in human non-alcoholic fatty liver disease models determined by matrix-assisted laser desorption/ionization mass spectrometry	Ruth Walker	Received

FRI-082	Peripheral blood mononuclear cells mitochondrial copy number and adenosine triphosphate inhibition test in non-alcoholic fatty liver disease	Eileen L. Yoon	Received

SAT-082	Regulation of NEAT1 in NAFLD by RNA-binding proteins	Lisa Ahne	Received

THU-082	Genetic risk of fatty liver disease and mortality in the general population	Helene Gellert-Kristensen	Received

SAT-083	Anti-inflammatory effect of simvastatin-ezetimibe combination therapy via inhibition of macrophage in NASH related mouse model	Seul Ki Han	Received

FRI-083	Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era	Dae Won JUN	Received

THU-084	The association between nonalcoholic fatty liver disease and insulin resistance within normal glucose level population	chun-yi Wang	Received

FRI-084	Assessing the applicability of non-invasive diagnostic tests (NITs) in non-alcoholic fatty liver disease: an international qualitative study	Maja Thiele	Received

SAT-084	The different modulation of KLB expression impacts on liver damage in NAFLD patients and in an in vitro model: a novel druggable target?	Marica Meroni	Received

THU-085	Chronic pruritus represents a major burden in non-cholestatic hepatobiliary disorders	Andreas Kremer	Received

SAT-085	Utilization of Gluconeogenic Glucose-6-Phosphate via Pentose Phosphate Pathway is increased in mice fed a high fat/high sugar diet compared to a high sugar diet alone	Getachew Debas Belew	Received

FRI-085	Evaluation of the performance of a novel digital pathology method for the continuous quantification of steatosis, ballooning and inflammation in liver biopsies and its correlation with NASH-CRN scores in patients with NASH	Louis Petitjean	Received

THU-086	Mortality prediction in non-alcoholic fatty liver disease using SteatoSITE: an integrated gene-to-patient data commons for high-definition non-alcoholic fatty liver disease research	Maria Jimenez Ramos	Received

FRI-086	Can combination of M2BPGi and APRI help endocrinologists refer patients with advanced hepatic fibrosis to hepatologists?	Mimi Kim	Received

SAT-086	A novel microwell platform to analyse single-cell secretion dynamics and cell communication in NAFLD progression	Richell Booijink	Received

FRI-087	The relationship between foetal head circumference growth trajectories and nonalcoholic fatty liver disease in adolescents	Jeffrey Lee	Received

THU-087	Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and liver cirrhosis in a prospective cohort	Hun Jee Choe	Received

SAT-087	Dysregulation of the urea cycle enzymes determines a more severe NAFLD phenotype in a DIAMOND preclinical model	Rocío Gallego-Durán	Received

SAT-088	Quantitative multimodal anisotropy imaging enables automated fibrosis assessment of H&E-stained tissue	Justin Lee	Received

FRI-088	Liver stiffness assessed by transient elastography predicts clinical events in patients with T2DM and NAFLD	Jesús Rivera-Esteban	Received

THU-088	Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease	Huapeng Lin	Received

THU-089	Hepatic fat as a novel marker for high-risk coronary atherosclerosis in Familial Hypercholesterolaemia: a CT-based study	Gavin Huangfu	Received

FRI-089	Repeated noninvasive liver biopsy surrogate LIVERFASt correlates with BMI and liver enzyme improvements	Mona Munteanu	Received

SAT-089	Zonated quantification of immunohistochemistry in steatotic livers	Cédric Peleman	Received

FRI-090	Increased liver stiffness on vibration controlled transient elastography (Fibroscan) as a predictor of all-cause mortality in people with fatty liver disease	Michael Braude	Received

SAT-090	CD161 expressing CD4 CD25hi T cells accumulate in the liver of obese patients with NASH	Rafael Kaeser	Received

THU-090	Nonalcoholic fatty liver disease impcat on cardiovascular disease death: a population-based study	Chaonan Jin	Received

THU-091	Sarcopenia is associated with the severity of metabolic associated fatty liver disease in elderly residents	xiaohui liu	Received

SAT-091	GL0034, A novel long-acting glucagon-like peptide 1 receptor agonist exhibits significant efficacy in aged db/db mouse model of non-alcoholic fatty liver disease (NAFLD)	Rajamannar Thennati	Received

FRI-091	Magnetic resonance imaging-based biomarker accurately identifies patients with nonalcoholic steatohepatitis and significant liver fibrosis: a multicentre, international, validation study	David Marti-Aguado	Received

THU-092	NAFLD patients scheduled for bariatric surgery present with a milder disease phenotype as compared to not morbidly obese NAFLD patients: analysis of a large real-world cohort	Monika Rau	Received

FRI-092	Diagnostic accuracy of MRE for staging hepatic fibrosis in patients with NAFLD	Manuel Romero Gomez	Received

SAT-092	Development of an ex vivo model for non-alcoholic fatty liver disease using precision-cut liver slices	Mei Li	Received

SAT-093	The neolignan honokiol can improve intestinal barrier dysfunction in fructose-induced liver damage in mice	Anja Baumann	Received

THU-093	Effects of SARS-CoV2 pandemic in a cohort of Italian NAFLD patients	Bernardo Stefanini	Received

FRI-093	Aldafermin quantitatively improves inflammation in a 24-week clinical trial in patients with nonalcoholic steatohepatitis	Tian Lan	Received

FRI-094	Clinical and economic evaluation of community-based preventative screening strategies for non-alcoholic fatty liver disease in people with Type-2 diabetes melllitus	Roberta Forlano	Received

SAT-094	Retrospective AI-based measurement of NASH histology (AIM-NASH) analysis of biopsies from Phase 2 study of Resmetirom confirms significant treatment-induced changes in histologic features of non-alcoholic steatohepatitis	Janani Iyer	Received

THU-094	A higher Fibrosis-4 (FIB-4) score is associated with higher healthcare costs and hospitalizations in patients with Nonalcoholic Steatohepatitis (NASH)	Elliot Tapper	Received

SAT-095	Insights to molecular mechanism of Essentiale: In vitro studies in hepatic cell lines HepaRG and steatotic HepaRG	Gert Fricker	Received

THU-095	Comparison of hepatic and cardiovascular damage between HIV patients with steatosis and NAFLD: role of metabolic alterations and low visceral adiposity	Felice Cinque	Received

FRI-095	Confounding factors in diagnostic performance of magnetic resonance elastography for staging liver fibrosis in patients with non-alcoholic fatty liver disease: an individual patient data meta-analysis	Manuel Romero Gomez	Received

THU-096	Impact of intermittent fasting on anthropometric and clinical outcomes in non-alcoholic fatty liver disease: systematic review and meta-analysis	Marcia Lange	Received

SAT-096	Exposure to the SARS-CoV-2 spike protein in an in vitro model of steatosis enhances hepatocyte oxidative stress: implications for COVID-19 and accelerated disease progression	Angus Jacobs	Received

FRI-096	Is it possible to identify nonalcoholic steatohepatitis and the associated degree of fibrosis by noninvasive methods in patients with MAFLD?	Marta Casado	Received

THU-097	The Burden of Liver Fibrosis in the Obese Population	Gres Karim	Received

FRI-097	The Potential Role of Fatigue in Identifying Patients with NASH and Advanced Fibrosis who Experience Disease Progression	Carey Escheik	Received

FRI-098	Novel digital pathology quantitative image analysis and AI method detects the treatment effects of NASH drug candidates with a performance that benchmarks imaging-based measurements	Mathieu Petitjean	Received

THU-098	Impact of screening and treatment of obstructive sleep apnea in non-alcoholic fatty liver disease	Kelsey Collins	Received

FRI-099	Translational fibrosis phenotypes between the 3D human NASH Spheroidal Model and clinical NASH samples	Louis Petitjean	Received

THU-099	Undiagnosed NAFLD in the Obese Population: In Sight, Out of Mind	Gres Karim	Received

FRI-100	Shear Wave Elastography, Transient Elastography and Enhanced Liver Fibrosis Test Use in the Assessment of Non-Alcoholic Fatty Liver Disease (NAFLD) in Real- World Practices	Carey Escheik	Received

THU-100	Prevalence of non-alcoholic steatohepatitis in patients undergoing laparoscopic cholecystectomy for gallstone with non-alcoholic fatty liver disease	Utpal Anand	Received

FRI-101	Diagnostic performance of AGILE 3 score for identification of advanced fibrosis and prediction of liver-related events in patients with non-alcoholic fatty liver disease	Ciro Celsa	Received

THU-101	Lack of awareness of a NAFLD pandemic in a high risk group. Is it time to act in primary care?	Maria Fernanda Guerra Veloz	Received

SAT-101	Efficacy and Safety of Leronlimab in Patients with Nonalcoholic Steatohepatitis: Topline Results of NASH01 Clinical Trial	Scott Hansen	Received

THU-102	Nonalcoholic fatty liver disease and type 2 diabetes: low referral rate of patients at increased risk of progressive liver disease	Lucy Gracen	Received

SAT-102	Reduced triglycerides and LDL cholesterol from once-weekly administration of the well-tolerated novel FGF21 analogue 0499	Kirsten Dahl	Received

FRI-102	Diagnostic accuracy of non-invasive tests for cirrhotic NASH - An individual participant data meta-analysis	Ferenc Mozes	Received

SAT-103	MULTIMODALITY ASSESSMENT OF HEPATIC FIBROSIS:RANKED PAIRED READING AND ARTIFICIAL INTELLIGENCE IDENTIFIES FIBROSIS IMPROVEMENT WITH ARAMCHOL MISSED BY CONVENTIONAL STAGING	Shani Ganon	Received

FRI-103	Longitudinal ALT trajectories are generally stable among patients with non-alcoholic fatty liver disease (NAFLD): An investigation using artificial recurrent neural networks	Michael Fried	Received

THU-103	Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease	Shunsuke Sato	Received

SAT-104	The effect of glucagon on rates of hepatic mitochondrial oxidation and pyruvate carboxylase flux in man assessed by positional isotopomer tracer analysis (PINTA)	Kitt Petersen	Received

FRI-104	An adult-based genetic risk score for hepatic fat associates with liver and lipid traits in Danish children and adolescents	Yun Huang	Received

THU-104	Statins, but not aspirin, reduce the risk of hepatocellular carcinoma and mortality in Danish patients with cirrhosis due to alcohol-related liver disease: a nationwide causal study	Frederik Kraglund	Received

FRI-105	Identification of new potential biomarkers to follow steatohepatitis in patients with Non-Alcoholic/Metabolic-associated Fatty Liver Disease	Douglas Maya	Received

SAT-105	Identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with Lanifibranor	jerome boursier	Received

FRI-106	NASH patients itinerary: Comparison of strategies for screening, referring and management	Manuel Romero Gomez	Received

SAT-106	TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in nonalcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study	Susan Huang	Received

SAT-107	Favorable lipid and pruritus profile of liver-distributed farnesoid X receptor agonist TERN-101 at clinically efficacious doses in nonalcoholic steatohepatitis phase 2a LIFT study	Susan Huang	Received

FRI-107	Peformance of FIBROMETER-derived biomarker panels for assessment of fibrosis stage in NAFLD: NIMBLE stage 1 and the NASH CRN Collaborative Study	Daniel Huang	Received

FRI-108	Diagnostic accuracy of non-invasive tests for fibrotic NASH - An individual participant data meta-analysis	Ferenc Mozes	Received

SAT-108	Liver-distributed farnesoid X receptor agonist TERN-101 demonstrates potent target engagement with a favorable exposure-response profile in nonalcoholic steatohepatitis patients	Susan Huang	Received

FRI-109	Multiparametric MRI biomarker corrected T1 as a prognostic marker in chronic liver disease	Cayden Beyer	Received

SAT-109	EDP-297: a novel, highly potent, farnesoid X receptor agonist, results of a phase 1 study in healthy subjects	Christine Marotta	Received

FRI-110	Results of the Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) study 1.1 on the reproducibility and repeatability of shear-wave and transient elastography in non-alcoholic fatty liver disease	Anthony Samir	Received

SAT-110	Weight loss with semaglutide treatment or time-restricted feeding differentially improves non-alcoholic steatohepatitis in diet-induced obese insulin resistant mice	Francois Briand	Received

SAT-111	ECC4703, a full thyroid hormone receptor beta (THRb) agonist, demonstrated excellent ivity and liver targeting properties and improvement of plasma lipid, NAFLD acitivty score and fibrosis in NASH animial model	Jianfeng Xu	Received

FRI-111	Independent association of physical activity with nonalcoholic fatty liver disease and alanine aminotransferase levels	Jun Kyu Lee	Received

SAT-112	LIVRQNac increases fatty acid oxidization in a primary human hepatocyte model of non-alcoholic steatohepatitis	Matthew Russell	Received

FRI-112	In a nonalcoholic steatohepatitis (NASH) clinical trial, baseline and screen failure magnetic resonance elastography (MRE) liver stiffness values calculated as weighted means were not different from values calculated as simple means	Michael Middleton	Received

SAT-113	Assessment of therapeutic effect of liraglutide in newly established cell culture model of nonalcoholic and drug-induced fatty liver disease	Tea Omanovic Kolaric	Received

FRI-113	Influence of pregnancy on NAFLD-associated lipidomic signatures	Tatyana Kushner	Received

FRI-114	Plasma sgp130 is an independent predictor of non-alcoholic fatty liver disease severity	AYSIM GUNES	Received

SAT-114	Efx treatment improved histopathology and noninvasive markers of liver injury and fibrogenesis to a similar extent in NASH patients with high-risk PNPLA3 genotypes, compared to those with lowest genetic risk: a post-hoc analysis of balanced study	Erik Tillman	Received

FRI-115	FIB-4 outperforms other serum non-invasive fibrosis tests in metabolic associated fatty liver disease	Nikoletta Maria Tagkou	Received

SAT-115	Oxygen-nutrient mismatch: a novel concept to explain how Obeticholic acid benefits NASH treatment	Gerond Lake-Bakaar	Received

FRI-116	PRESENCE OF AUTO-ANTIBODIES HAS NO IMPACT ON HISTOLOGICAL PARAMETERS IN NON-ALCOHOLIC FATTY LIVER DISEASE	AJEET SINGH BHADORIA	Received

SAT-116	Sustained reduction of triglyceride and LDL cholesterol from single administration of the novel long-acting FGF21 analogue 0499	Kirsten Dahl	Received

FRI-117	Marked underestimation of liver fat content as measured by magnetic resonance versus histologya systematic review and meta-analysis	Sami Qadri	Received

SAT-117	Combination of an Acetyl-CoA carboxylase inhibitor and obeticholic acid reduced lipids and bile acids and altered lipid and amino acid metabolism in the liver of humanized mice	David Hollenback	Received

SAT-118	Identification of a fibrosis endotype in NAFLD patients more prone to interventions aimed at reducing fibrogenesis	Mette Juul Fisker	Received

FRI-118	DISEASE SEVERITY ASSESSMENT OF METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IN TAIWAN	Jee-Fu Huang	Received

SAT-119	The pan-PPAR agonist lanifibranor improves markers of cardiometabolic health in patients with NASH independent of weight change	Michael Cooreman	Received

FRI-119	Optical analysis of liver magnetic resonance images (MRI) 3T to detect steatohepatitis features: the program DeMILI 3.0.	Isabel Fernández-Lizaranzu	Received

SAT-120	Lanifibranor therapy reduces the FibroScan-aspartate aminotransferase (FAST) score associated with histological NASH resolution and improvement of fibrosis and biomarker response	Michael Cooreman	Received

FRI-120	The Fibrosis-4 cut-off value for significant fibrosis is dependent on the type of non-alcoholic fatty liver disease patients	Leen Heyens	Received

SAT-121	Effect of smartphone-assisted lifestyle intervention in patients with metabolic-associated fatty liver disease (MAFLD): a preliminary analysis of a randomized controlled trial	Suraphon Assawasuwannakit	Received

FRI-121	Developing an algorithm to predict NAFLD in clinical trial volunteers - interim report NCT04873258	Dominic Pimenta	Received

FRI-122	Correlation of Ultrasound derived Fat Fraction (UDFF) with MRI (PDFF): Possibilities and Analysis of Confounding Factors	Reinhard Kubale	Received

SAT-122	Efficacy and mechanism of time-restricted fasting in non-alcoholic liver disease	Jiang Deng	Received

FRI-123	ELF to identify NASH and fibrosis in non-alcohol related fatty liver disease	Richard Parker	Received

SAT-123	Functionalizing novel cancer related genes in liver disease and liver regeneration	Nooshin Nourbakhsh	Received

SAT-124	Effect of long-term dietary intervention on liver pathology and markers of hepatocellular senescence in the GAN diet-induced obese mouse model of NASH	Kristoffer Voldum-Clausen	Received

FRI-124	Performance of the Steatosis-Associated Fibrosis Estimator (SAFE) to predict F2 fibrosis and higher in a cohort of South Korean patients with non-alcoholic fatty liver disease (NAFLD)	Vivek Charu	Received

FRI-125	FIB-4 combined with positron emission tomography biomarkers detects fibrotic NASH	Souvik Sarkar	Received

SAT-125	Fecal microbiota trasplant using endoscopic-placement hydrogel reduces liver fibrosis with no changes in steatosis in a rat model of steatohepatitis with fibrosis	Ramon Bartolí	Received

SAT-126	Reversing diet-induced steatohepatitis and CCl4 induced fibrosis with AN1284 treatment	Rinat Abramovitch	Received

FRI-126	Mitochondria-derived methylmalonic acid is associated with advanced fibrosis risks in metabolic dysfunction-associated fatty liver disease (MAFLD): results from the NHANES 1999-2004	Qi Huang	Received

SAT-127	Spontaneous and drug-induced histological changes in nonalcoholic steatohepatitis: an assessment by meta-analysis of trials	Grazia Pennisi	Received

SAT-128	Synergistic activity of GLP-1 peptide analog XW003 and the long-lasting GIP receptor agonist XW017 in a diet induced obese mouse model	Martijn Fenaux	Received

SAT-129	Preclinical pharmacology of low molecular weight GLP-1 receptor agonist XW014	Martijn Fenaux	Received

SAT-130	Integrated transcriptomics of CRV431 treatment in a Phase 2a NASH trial confirms anti-fibrotic effect of pan-cyclophilin inhibition and identifies CRV431-specific biomarkers	Patrick Mayo	Received

SAT-131	Pharmacokinetic (PK) and pharmacodynamics (PD) of BIO89-100, a novel glycoPEGylated FGF21, in nonalcoholic steatohepatitis (NASH) patients with compensated cirrhosis	Naim Alkhouri	Received

SAT-132	HEC96719, a novel tricyclic farnesoid X receptor agonist for treatment of non-alcoholic steatohepatitis: results of preclinical study and phase I trial	Yan Wang	Received

SAT-133	Effect of saroglitazar in reducing liver enzymes and liver stiffness in non-alcoholic fatty liver disease: a single arm prospective study	Avisek Chakravorty	Received

SAT-134	Intrahepatic microcirculation disorders and hyperammoniemia and their correction at nonalcoholic steatohepatitis patients with initial stages of liver fibrosis	Tatiana Ermolova	Received

SAT-135	Ticagrelor, but not clopidogrel, attenuated hepatic steatosis in a model of non-alcoholic fatty liver disease	Hyunwoo Oh	Received

SAT-136	Lemon balm extract ALS-L1023, an angiogenesis inhibitor, inhibits liver fibrosis in a non-alcoholic fatty liver disease model	Hyo Young Lee	Received

SAT-137	Hepatocyte-specific JNK signaling is protective during progression of NASH	Julia Piche	Received

SAT-138	Semaglutide use in adjunct to multidisciplinary lifestyle interventions improves weight and body composition in NAFLD patients	Rochelle Wong	Received

SAT-139	Pegozafermin improved liver histology, liver-related non-invasive tests (NITs) and metabolic profiles in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)	Maya Margalit	Received

SAT-140	Identification of new therapeutic targets for hepatic regenerative medicine in Non-Alcoholic Fatty Liver Disease (NAFLD)	Shainan Hora	Received

SAT-141	The effects of dietary vitamin E intake on NAFLD and sex differences in serum metabolic profile	Carolin Schneider	Received

SAT-142	Favorable safety profile of TERN-201, a highly ive inhibitor of vascular adhesion protein-1, in the nonalcoholic steatohepatitis phase 1b AVIATION study	Susan Huang	Received

SAT-143	Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)	Naim Alkhouri	Received

SAT-144	Novel thyroid hormone receptor-beta agonist TG68 safely induces hepatic fat reduction in a non-alcoholic steatohepatitis rat model	Andrea Marco Caddeo	Received

SAT-145	Safety and pharmacokinetics (PK) of single and multiple ascending oral doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist for the treatment of non-alcoholic steatohepatitis (NASH) , in healthy volunteers and subjects with hyperlipidemia	Benedetta Massetto	Received

FRI-146	Hepatic angiocrine HGF attenuates liver fibrogenesis via modulation of PDK1/AKT axis	Jianye Wang	Received

SAT-146	A MEDITERRANEAN DIET INTERVENTION has BENEFICIAL EFFECTS on BIOMARKERS of CARDIOVASCULAR RISK and HEPATIC FIBROSIS in NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)	Laura Haigh	Received

FRI-147	Bisphosphonate-loaded nanogels attentuate liver fibrosis by repolarization of M2-type macrophages	Leonard Kaps	Received

FRI-148	Preclinical evaluation of the calpain inhibitor BLD-3051 as a therapeutic strategy for liver fibrosis	Ravi Rajagopalan	Received

FRI-149	Experimental fibrosis alters matrix-bound vesicles cargo that do not revert after histologic recovery	Toshifumi Sato	Received

FRI-150	Hepatocyte cell-specific deletion of cathepsin D does not affect liver inflammation and fibrosis during cholestatic-induced liver fibrosis	Maria Fernandez-Fernandez	Received

SAT-151	CD44 plays critical role in liver regeneration through enhanced redox balancing	Wan Seob Shim	Received

FRI-151	The therapeutic potential of alpha v integrins in liver fibrosis	Syedia Rahman	Received

THU-151	Altered fecal microbiome and metabolome in hepatitis B related chronic liver diseases	YUE SHEN	Received

THU-152	The therapeutic effect of Lactobacillus plantarum on metabolic phenotypes in non-alcoholic fatty liver disease mice model	Dong Yun Kim	Received

SAT-152	Development of ECM mimicking 3D-hydrogel scaffolds for liver tissue engineering	Nathan Carpentier	Received

FRI-152	Dual inhibition of integrins alpha-v/beta-6 and alpha-v/beta-1 decreases portal pressure and liver fibrosis in rats with biliary cirrhosis	Philipp Knigshofer	Received

SAT-153	Three-dimensional conditions in a perfusion bioreactor to support maturation of human amnion epithelial stem cells into functional hepatocyte-like cells	Sara Campinoti	Received

FRI-153	Dual roles of PSMP/MSMP in the progression of hepatic fibrosis and hepatocellular carcinoma	Shaoping She	Received

THU-153	Stool microbiota, compared to salivary microbiota, show more extensive correlations with plasma metabolites in decompensated cirrhosis in a multinational cirrhosis cohort	I. Jane Cox	Received

THU-154	The gut virome in non-alcoholic fatty liver disease: distinct changes in Phapecoctavirus composition in a human microbiota associated animal model	Hau-Tak Chau	Received

FRI-154	NKT cells promote both type 1 and type 2 inflammatory responses in the non-obese diabetic inflammation and fibrosis (NIF) mouse model	Sofia Mayans	Received

SAT-154	Knockdown of Glyoxylate reductase/hydroxypyruvate reductase (GRHPR) accelerates liver regeneration and decreases chronic liver damage	Viktoriia IAKOVLEVA	Received

SAT-155	Expression and function of axon guidance genes in the developing portal tract	Lila Gannoun	Received

FRI-155	Using qFibrosis analysis to predict disease and survival outcome of patients with hepatocellular carcinoma after curative treatment	Elaine Chng	Received

THU-155	Mitochondrial hyperactivation determines a transferable protective gut microbiota profile in metabolic-associated fatty liver disease development	María Juárez-Fernández	Received

THU-156	Fecal transplant-related reductions in Alcohol intake from human to mice are associated with alterations in the intestinal but not liver or prefrontal cortex transcriptome	Jasmohan S Bajaj	Received

FRI-156	Multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in animal model of NASH/fibrosis	Jong Suk Lee	Received

SAT-156	Patients with chronic liver diseases are at risk for diabetes even before development of cirrhosis	Georgia Bale	Received

THU-157	New insights from mapping of the mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation	Mikal Jacob Hole	Received

FRI-157	Direct anti-inflammatory and anti-fibrotic effects of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in thioacetamide-induced mouse model of liver injury and fibrosis	Jung Kuk Kim	Received

SAT-157	Characterization of bioengineered liver constructs using hepatoblast organoids (HBOs) and human liver extracellular matrix (ECM) 3D-platforms	Margarita Papatheodoridi	Received

FRI-158	Loss of bile salt export pump (BSEP/ABCB11) protects mice from development of carbon tetrachloride (CCl4) induced hepatic fibrosis	Claudia Fuchs	Received

THU-158	Designing a polymetabolic risk score for non-alcoholic steatohepatitis patients by differentiating their metabolic profiles from healthy controls	Nadeen Habboub	Received

SAT-158	Novel avenue towards liver regeneration and treatment of acute and chronic liver diseases: safety and PK profile from a first-in human (FIH) clinical trial for HRX-0215 as first in class MKK4 inhibitor	Wolfgang Albrecht	Received

THU-159	Intestinal hyperpermeability in cirrhosis is predictive for survival and associated with distinct microbiome changes	Vanessa Stadlbauer	Received

FRI-159	Large-scale multicenter study for the clinical utility of the non-invasive biomarkers Gas6 and soluble Axl in hepatocellular carcinoma, liver fibrosis and end-stage liver disease	Wolfgang Mikulits	Received

SAT-160	In vivo loss-of-function studies unravel protein tyrosine phosphatase delta as a regulator of liver regeneration during metabolic liver disease	Armando Andres ROCA SUAREZ	Received

FRI-160	Multispectral analysis of liver biopsies from patients with chronic hepatitis C reveals unique macrophage phenotypes and spatial interactions associated with fibrosis progression	Omar Saldarriaga	Received

SAT-161	Integrated proteomics and metabolomics analysis reveals canonical and novel regulatory pathways linked to liver regeneration in living donor liver transplant (LDLT) Donors	Gaurav Tripathi	Received

FRI-161	Neutrophil-specific NLRP3 activation triggers liver inflammation and fibrosis	Benedikt Kaufmann	Received

THU-161	A nine-strain bacterial consortium improves portal hypertension and insulin signaling and delays non-alcoholic fatty liver disease progression in vivo	Aurora Barbera	Received

FRI-162	Imaging of fibrosis in metabolic associated liver disease by a radiolabeled affibody targeting PDGFRB	Olivia Wegrzyniak	Received

SAT-162	Regulation of extracellular Nicotinamide adenine dinucleotide in patients with liver fibrosis: new insights into conventional hepatobiliary parameters	Can Kamali	Received

THU-162	Duodenal permeability is associated with mucosal microbiota in compensated cirrhosis	Patricia Bloom	Received

THU-163	Impact of phenylacetic acid, a microbiota derived-metabolite, on hepatic endoplasmic reticulum-mitochondria interactions and steatosis	Rémy Lefebvre	Received

FRI-163	Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece	Konstantinos Manganas	Received

THU-164	Dynamics of the gut-liver axis in rats with varying fibrosis severity	Hongyan Xiang	Received

FRI-164	Hemodynamic, molecular, and histological characterization of a toxic liver fibrosis regression model	Philipp Knigshofer	Received

SAT-164	Embryogenesis of human fetal liver at various stages of gestation: a histomorphometric study	Pooja Bhadoria	Received

SAT-165	Generation of universal low-immunogenic human cholangiocyte organoids for treatment of cholangiopathies	Sandra Petrus-Reurer	Received

FRI-165	The upper limit of normal of alanine aminotransferase (ALT) in diagnosing liver disease and fibrosis by the Intelligent Liver Function Test (iLFT) system	Jeremy Lee	Received

FRI-166	Inhibition of 11beta-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH	Haeng Ran Seo	Received

SAT-166	Opposite PAR2 roles in liver regeneration from autoimmune or direct damage. Solving the conflict	Gal Reches	Received

THU-167	Increased expression of programmed cell death ligand 1 and galectin 9 in transplant recipients who achieved tolerance after immunosuppression withdrawal	Nguyen Hai Nam	Received

SAT-167	Chronic injury induces plasticity between cholangiocytes and hepatocytes in the human liver	VASILEIOS GALANAKIS	Received

FRI-167	Anti-fibrotic effects of microRNA-9-5p and microRNA-122	Dana Eidelshtein	Received

SAT-169	The hepatocellular vitamin D receptor regulates liver regeneration after partial hepatectomy	Harendran Elangovan	Received

THU-169	Toll-like receptor 3 polymorphisms rs5743305 and rs3775291 affect innate immune responses in whole blood analyses	Sophia Barkow	Received

SAT-170	Selective induction of macrophage RNF41 stimulates liver regeneration in hepatectomized healthy and fibrotic mice	Alazne Moreno-Lanceta	Received

THU-170	IL-15 boots HBV-specific CD8 cell response by activated progenitor pool mitochondrial remodelling in on treatment e-Ag negative chronic hepatitis B	Julia Peña Asensio	Received

FRI-170	MAIT cell inhibition promotes liver fibrosis regression by reprogramming macrophage phenotype	Morgane MABIRE	Received

FRI-171	The LiverPRO score, a multivariable model for prediction of significant fibrosis in primary care: derivation, validation and comparison with FIB-4 and ELF-test in 5,000 study participants	Katrine Lindvig	Received

THU-171	Mucosal-associated invariant T cells are rendered functionally exhausted within the tumour microenvironment in HCC in a cell-contact dependent manner	Junika Pohl	Received

SAT-171	Generation of functional ductal organoid with biliary tree network in decelluarized liver scaffold	Jiaxian Chen	Received

SAT-172	Molecular basis of hepatic differentiation of human bone marrow mesenchymal stem cell in vivo	Dongyan Shi	Received

THU-172	Preclinical model for the study of immune responses specific for a hepatic-self-antigen	Anas Cardon	Received

FRI-172	The protective effect of time-caloric restriction in liver fibrosis induced by nitrosamines in rat model	Christian Molina-Aguilar	Received

FRI-173	Macrophage MerTK promotes a profibrogenic cross-talk with hepatic stellate cells via soluble mediators	Mirella Pastore	Received

SAT-173	Dynamic alterations of metabolites revealed the vascularization progression of bioengineered liver	Qian Zhou	Received

THU-173	Proximity labelling reveals potential cis interactions of CD52 glycoprotein counter-receptors on circulating CD4HLA-G regulatory T cells in acute decompensation of cirrhosis	Tong Liu	Received

THU-174	Humoral and cellular immunity after vaccination against SARS-CoV-2 is reduced in patients with chronic liver disease	Hevar Hamah Saed	Received

FRI-174	Comparative fibrosis-reducing activities of farnesoid X receptor (FXR), peroxisome-proliferator activated receptor delta (PPAR) and thyroid hormone receptor (THR) agonists in the carbon tetrachloride mouse model	Edward Cable	Received

THU-175	Efficacy of branched-chain amino acid granules to restore innate immunity in cirrhosis-associated immune dysfunction: a randomized controlled trial	Natthapat Rujeerapaiboon	Received

THU-176	The close correlation between sarcopenia and the phagocytic dysfunction in respond to bacterial pathogen Ecoli in cirrhotic patients	NATTHAPAT RUJEERAPAIBOON	Received

FRI-176	The modulation of NADPH oxidases by tyrosol-derived phenolic compounds prevents hepatic fibrogenesis	Daniela Gabbia	Received

THU-177	Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis	Apichat Kaewdech	Received

SAT-177	Pharmacologic inhibition of HSD17B13 is hepatoprotective in mouse models of liver injury	Manuel Roqueta-Rivera	Received

FRI-177	Exploring gender-related differences in liver fibrosis and regeneration through a new experimental carbon tetrachloride protocol in mice	Katia Sayaf	Received

SAT-178	Inhibition of NLRP3 inflammasome by GPR40 agonists	Jeongwoo Park	Received

THU-178	Predictive immune biomarkers to safely discontinue nucleos(t)ide analogue treatment in HBeAg negative chronic hepatitis B (NUC-B study)	Sandra Phillips	Received

FRI-178	Multicenter external validation of FIB-6: a novel, machine-learning, simple bedside score to rule out severe liver fibrosis and cirrhosis in patients with MAFLD	Gamal Shiha	Received

FRI-179	A bioengineered approach to re-create and study the extracellular matrix-immune cell crosstalk in normal and fibrotic liver	Sara Campinoti	Received

SAT-179	Role of Monocyte chemoattractant protein-induced protein 1 in liver fibrosis and activation of hepatic stellate cells	Natalia Pydyn	Received

THU-179	MAIT-cells in blood are associated with a higher risk of infection in patients with cirrhosis	Hannes Hagstrm	Received

THU-180	Fatty acids directly limit mucosal-associated invariant T cell effector function in non-alcoholic fatty liver disease	Sebastian Deschler	Received

FRI-180	Clinical and genetic factors associated with regression of fibrosis in ACLD after etiological therapy	Yuly Paulin Mendoza	Received

SAT-180	The genomic landscape of IDH1 mutant intrahepatic cholangiocarcinoma: a multicentre comprehensive analysis	margherita rimini	Received

THU-181	Multimodal single cell analysis reveals the basis for butyrate induction of TNF?-secreting regulatory T cells	Mo Atif	Received

FRI-181	Addressing the heterogeneity of fibrosis in liver biopsy specimens with qFibrosis -- a new paradigm for an old problem	Elaine Chng	Received

SAT-181	Isolation of hepatocytes from various liver tissues by a novel, semi-automated perfusion technology	Carsten Poggel	Received

FRI-182	Characterisation of the novel Galectin-3 inhibitor GB1107 on CCl4-induced liver fibrosis in mice	Alison MacKinnon	Received

THU-182	COVID-19 vaccination in liver cirrhosis: safety and immune and clinical responses	Maria Ins Canha	Received

FRI-183	Quantitative digital pathology of 3D human NASH models establish continuous scores to evaluate the antifibrotic effects of Selonsertib, Firsocostat and Resmetiron	Louis Petitjean	Received

SAT-183	Ptpn1 deletion protects oval vells against lipoapotosis by favoring lipid droplet formation and dynamics	Pilar Valdecantos	Received

SAT-184	Accurate detection of HBV splice variant DNA by using long-read sequencing	Sanne Hulspas	Received

THU-184	Patients with decompensated cirrhosis and liver transplant recipients demonstrate poor humoral and cellular immune response against COVID-19 vaccine	Anand Kulkarni	Received

FRI-184	Etiology-independent fibrosis severity scoring by quantitative digital pathology image analysis	Adam Watson	Received

FRI-185	Liver stiffness and autoimmune profile in a cohort of patients with systemic sclerosis	Davide Di Benedetto	Received

THU-185	Presence of cirrhosis in chronic liver disease patients associates with a lower immune response to COVID-19 vaccines - a multicenter european study	Rui Castro	Received

SAT-185	The identification and characterization of novel bile acid-derived Farnesoid X Receptor agonists	Dannielle Kydd-Sinclair	Received

FRI-186	Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis	Alexandru Popa	Received

THU-186	Heterogeneity of peripheral blood monocytes in patients with cirrhosis	Anne Geng	Received

SAT-186	SARS-CoV-2 induces pericyte procoagulant response associated with portal vein microthrombosis and intrapulmonary vascular dilations in fatal COVID-19	Luca Fabris	Received

SAT-187	Dual ileal/renal-liver bile acid transporter inhibitors with different transporter ivity in vitro differentially increase faecal and urinary bile acid excretion in organic anion transporting polypeptide 1a/1b knockout mice in vivo	Paris Fossa	Received

THU-187	JAM-A is a multifaceted regulator in hepatic fibrogenesis, supporting LSEC integrity and stellate cell quiescence	Jonathan Frederik Brozat	Received

FRI-187	Inhibition of tumour progression locus 2 (TPL2) halts the progression of liver fibrosis in a stringent long term choline deficient high-fat diet (CdHFD) rat model	Milessa Afonso	Received

FRI-188	Evaluation of the antifibrotic effects of naringenin, asiatic acid and icariin by using precision-cut liver slices of mouse and human	Ke Luo	Received

SAT-188	Integrated bile lipidome and meta-proteome analysis classifies lipid species and microbial peptides predictive of carcinoma of the gall bladder	Nupur Sharma	Received

SAT-189	The effects of apurimic/apirimidinic endonuclease 1 as a sensitizer to sorafenib in hepatocellular carcinoma	Nataliya Rohr-Udilova	Received

THU-189	Multi-omics analysis of human livers reveals variation in intrahepatic inflammation across chronic hepatitis B infection phases	Andre Boonstra	Received

THU-190	Liver cirrhosis and cirrhosis etiology impacts the circulating immune mediators of early stage hepatocellular carcinoma	Andre Boonstra	Received

FRI-190	Multispectral imaging analysis of liver biopsies from patients with non-alcoholic steatohepatitis reveals enrichment of pathogenic macrophage phenotypes associated with disease progression	Joseph Gosnell	Received

THU-191	Ebola virus infection promotes reduced gene expression of antigen presentation molecules in hepatic CD68 macrophages in cynomolgus macaques	Timothy Wanninger	Received

SAT-191	Soluble guanylyl cyclase expression and signaling in different types of liver fibrosis	Ksenia Brusilovskaya	Received

FRI-191	Diabetes, but not prediabetes, is associated with significant liver fibrosis	Won Sohn	Received

FRI-192	Lysophosphatidylserine may stimmulate liver fibrosis	Takako Nishikawa	Received

THU-192	Plasmalemma vesicle-associated protein expression is driven by senescent cell-endothelial crosstalk and shapes the immune landscape in chronic liver disease	Alex Wilkinson	Received

SAT-192	Impact of maternal obesity on liver disease in the offspring: a comprehensive transcriptomic analysis and validation of results	Beat Moeckli	Received

SAT-193	Liver directed in utero AAV gene therapy for maple syrup urine disease in a neonatal lethal murine model	Kate Mullany	Received

FRI-193	Quantitative assessment of liver fibrosis in NASH patients	Luong Ruiz	Received

THU-193	Dysfunctional liver-resident CXCR6 CD8 T cells during persistent viral liver infection	Miriam Bosch	Received

THU-194	Fate of HDV-specific CD8 T cells during bulevirtide monotherapy in patients with chronic hepatitis delta	Valerie Oberhardt	Received

FRI-194	Second harmonic generation microscopy can quantify and subclassify early stages of NASH fibrosis progression: data from a screen-failure cohort of a NASH phase 2 study	Philip OGorman	Received

SAT-194	Patient-derived hepatocellular carcinoma organoids as predictors of Treatment Response	kyungjoo cho	Received

SAT-195	Dissecting A-to-I RNA editome of liver macrophages in non-alcoholic fatty liver disease	Achilleas Fardellas	Received

THU-195	Increased ILT2 expression contributes to dysfunction of CD56dimCD16NK cells in chronic hepatitis B virus infection	Yingzhi Zhang	Received

SAT-196	Restoring bone marrow hematopoietic stem cells (BM-HSC) reserve augments regression of fibrosis and regeneration in animal model of cirrhosis	Nidhi Nautiyal	Received

THU-196	Elevated serum bilirubin levels and aminotransferases are associated with immuno-modulatory and suppressive subsets in pregnant females with intrahepatic cholestasis and hepatitis E virus infection	Anoushka Saxena	Received

FRI-196	Endothelin receptor A antagonist functionalized magnetic nanoparticles as a promising approach for the treatment of liver fibrosis	Marit ten Hove	Received

THU-197	Classification of HCV-specific CD8 T cells by the differential expression pattern of Slamf6 and CD69 predicts that the majority of cells are rather preterminally versus terminally exhausted regardless of disease stage	Maximilian Knapp	Received

SAT-197	Human resident liver macrophages protect against metabolic stress in obesity	Emelie Barreby	Received

FRI-197	3D human NASH model as a screening-based discovery approach for ing and prioritizing drug candidates	Radina Kostadinova	Received

SAT-198	Reversal of epithelial-mesenchymal transition in a cholangiocarcinoma cell line by genetic targeting of sulfatide synthesis	Gloria Alvarez Sola	Received

THU-198	TAPBPR shapes the hepatitis B immunopeptidome presented on HLA class I molecules	Ricky Sinharay	Received

FRI-198	Investigating the function of Endothelial-To-Mesenchymal Transition during liver fibrogenesis using a Liver-On-A-Chip platform	Neil Dufton	Received

FRI-199	Discovery of AMS-III-1086, a novel LPA1 antagonist for the treatment of liver fibrosis and liver cirrhosis	Jung-Hee Kim	Received

SAT-199	Unravelling the circadian transcriptome and epigenome of the human liver	ATISH MUKHERJI	Received

THU-199	Phenotypes of NK cells and the activation profile of T cells in the early stages of alcohol liver diseases	paola zuluaga blanco	Received

FRI-200	Integrated spatial-temporal mathematical liver lobule model for simulation of fibrotic wall formation	Steven Dooley	Received

THU-200	A spatio-temporal map of malaria infected mouse liver	Franziska Hildebrandt	Received

SAT-200	Single-cell dynamics of interacting mesenchymal and leukocyte populations in advanced NASH	Kamilla Hejn	Received

SAT-201	Dysregulated glutamine metabolism in intrahepatic cholangiocarcinoma: a perspective for targeted therapy	Michela Anna Polidoro	Received

FRI-201	Telomerase-null mice display defective immune activation following the induction of liver fibrosis with S. mansoni	Willian Gomes	Received

FRI-202	Multiplexed digital spatial protein profiling reveals potential non-invasive biomarkers to predict advanced fibrosis	Chang Min Kim	Received

SAT-203	Mcpip1 fl/fl LysM Cre mice as an animal model of TNFa-dependent liver endothelial cell dysfunction in humans with chronic inflammation	Jerzy Kotlinowski	Received

FRI-203	Sex and diagnosis-specific differences in liver elastography and attenuation	Zhi Xin Tan	Received

SAT-204	Peroxisome proliferator activated receptor gamma regulates patatin-like phospholipase domain-containing protein 3 in adipocytes in vitro and in vivo in a mouse model of nonalcoholic steatohepatitis	Emmanuel Dauda Dixon	Received

FRI-204	Progression of liver disease among patients with a new diagnosis of protease inhibitor ZZ alpha-1 antitrypsin deficiency	Ed Marins	Received

FRI-205	Perihepatic implantation of matrix-embedded endothelial cells reduce inflammation and collagen deposition in fibrotic mice	Mireia Medrano-Bosch	Received

SAT-205	Animal variants of sodium-taurocholate co-transporting polypeptide permitting hepatitis B virus infection	Fuwang Chen	Received

SAT-206	Cholangiorcarcinoma-on-chip: a platform for 3D liver tumour model	Michela Anna Polidoro	Received

FRI-206	LncRNA XR_592974.2 and circRNA _2599 regulated hypoxic stress response in hepatic stellate cells by targeting the miRNA-145/JMY/P53 pathway	Dan Zhou	Received

FRI-207	Magnetic resonance elastography (MRE) demonstrate the strongest correlation with digital pathology and NASH CRN fibrosis assessments, compared to transient elastography and other assessed non-invasive tests (NITs)	Miljen Martic	Received

SAT-207	Regulation of cholangiocyte ciliogenesis by soluble adenylyl cyclase	Hang Lam Li	Received

SAT-208	CRISPR perturbation in iPSC-derived hepatic stellate cells reveals role for TNF-driven interferon response in chronic liver disease	Kelly Haston	Received

SAT-209	Regulation of cholangiocyte ciliogenesis by soluble adenylyl cyclase	Hang Lam Li	Received

FRI-209	Selectivity matters: Novel ROCK2 inhibitor down-regulates established liver fibrosis via concurrent of targeting inflammatory, fibrotic and metabolic pathways	Alexandra Zanin-Zhorov	Received

SAT-210	Signal transducer and activator of transcription 3 (STAT3)-driven hepatic transcriptional changes are indicative of a shift from immune tolerance to immune activation in chronic hepatitis B virus (HBV) infection	Jinglin Tang	Received

FRI-210	Aldafermin rebalances collagen turnover in patients with NASH and liver fibrosis in the ALPINE 2/3 study	Lei Ling	Received

SAT-211	Polymeric nanomicelles formulation of LY2157299-Galunisertib improves therapeutic outcome by greater reducing fibrosis and ameliorating fatty degeneration in a CCL4-induced hepatic-fibrosis rat-model	Marco Fidaleo	Received

SAT-212	3D bioprinted hepatocyte and mesenchymal stem cell spheroids as a cell therapy for liver disease.	Sam Wadsworth	Received

SAT-213	Fibroblast growth factors are therapeutic targets for radiofrequency ablation induced tumorigenesis	Aurelia Markezana	Received

SAT-214	Glycine ameliorates paracetamol-induced liver injury in non-alcoholic fatty liver disease by supporting glutathione biosynthesis	Alia Ghrayeb	Received

FRI-214	Use of the enhanced liver fibrosis test to risk stratify patients in the intelligent liver function test pathway: ruling out cirrhosis and advanced fibrosis	Madeline Pearson	Received

FRI-215	Comparison of CT, blood test, elastometry and their combination for non-invasive staging of liver fibrosis	Paul Calès	Received

SAT-215	Hepatocyte-specific deletiton of the anti-apoptotic Mcl-1 in mice induces polyploidization, mitotic erros and chromosomal instability.	Laure-Alix Clerbaux	Received

SAT-216	Hepatic inflammation elicits production of proinflammatory netrin-1 through exclusive activation of translation	Romain BARNAULT	Received

FRI-216	Reliability criteria of non-invasive tests for liver fibrosis	Paul Calès	Received

SAT-217	A meta-analysis to identify novel candidate genes in the development of hepatocellular carcinoma	Andrew Walakira	Received

THU-217	Reducing the risk of liver cirrhosis and hepatocellular carcinoma after treatment for smoking cessation in patients with chronic hepatitis B or C infection: a 12-year follow-up study	Yuan Tsung Tseng	Received

FRI-217	Metabolomic profiling of capillary dry blood samples for the differential diagnoses of hepatocellular carcinoma and liver diseases	Philipp Brunnbauer	Received

THU-218	Testing coverage and strategy required to sustain Hepatitis C elimination in an injecting network of people who inject drugs: a network-based model	RYan Buchanan	Received

FRI-218	Stable rates of cirrhosis diagnosed by Fibroscan despite changing trends in liver disease epidemiology: a single centre retrospective cohort study	Joan Ericka Flores	Received

FRI-219	Comparative assessment of noninvasive methods (NIMs)- LIVERFASt, liver stiffness measurement (LSM) with transient elastography (TE, Fibroscan) ELF and FiB-4 - in a prospective cohort with chronic liver diseases (CLD) from a tertiary liver center	Mona Munteanu	Received

THU-219	Hepatocellular carcinoma screening trends in individuals with cirrhosis in North Carolina	Christine Hsu	Received

FRI-220	Diagnostic accuracy of non-invasive imaging modalities for the diagnosis of liver cirrhosis compared to histological assessment in a clinical setting	Mira Thing	Received

THU-220	Cost- effectiveness evaluation of the hepatitis C elimination strategy in Cyprus in the era of affordable direct-acting antivirals	Ilias Gountas	Received

THU-221	Rethinking the management of chronic hepatitis B in the context of rural sub-saharan Africa: results from a social justice mixed methods study in rural Senegal (the AmBASS-PeCSen study)	Marion Coste	Received

FRI-221	Use of Fibrosis-4 (FIB-4) in liver fibrosis screening: which thresholds to choose?	denis ouzan	Received

FRI-222	Plasma cell-free DNA methylation as biomarker for hepatocellular carcinoma	María Gárate-Rascón	Received

THU-222	Global survey of healthcare workers attitudes to treatment of chronic hepatitis C infection in children and adolescents	Farihah Malik	Received

FRI-223	A derivation and validation study of paired liver and plasma proteomics in 659 individuals reveals circulating biomarkers for alcohol-related liver disease	Maja Thiele	Received

THU-223	Impact of community-based campaign in United States to increase hepatitis B virus screening and linkage to care among Asian immigrants from high endemic countries	Sung Kwon	Received

THU-224	The prognostic implications of liver function test abnormalities in patients admitted to hospital with COVID-19	Raza Malik	Received

FRI-224	Development and validation of a hepatic vascular geometrical model for noninvasive diagnosis of clinically significant portal hypertension in cirrhosis (CHESS1802)	Chengyan Wang	Received

FRI-225	The diagnostic accuracy of ElastQ 2-D shear wave elastography for liver fibrosis risk assessment in a mixed etiology, multinational cohort	David JM BAUER	Received

THU-225	A novel prognostic model including liver function parameters accurately predicts 30-day mortality in patients admitted with COVID-19	Raza Malik	Received

FRI-226	Machine learning models for prediction of severe portal hypertension in patients with compensated cirrhosis	Oleksandr Petrenko	Received

THU-226	Low health literacy is associated with higher healthcare service utilisation and costs among patients with cirrhosis	Elizabeth Powell	Received

FRI-227	Reproducibility and applicability of spleen stiffness measurement by vibration controlled transient elastograghy in patients with and without chronic liver disease	Giulia Francesca Manfredi	Received

THU-227	A modelling approach to estimate alcohol-related liver morbidity and mortality in France	Claire Delacte	Received

THU-228	A model to predict drinking population at-risk of liver disease in France: a tool for decision-making public health policies	Claire Delacte	Received

FRI-228	Validation of the continuous controlled attenuation parameter (CAPc) using the MRI-PDFF as reference	Anne LLORCA	Received

FRI-229	A novel non-invasive index for the prediction of liver fibrosis in chronic hepatitis B patients with concurrent nonalcoholic fatty liver disease	Jie Li	Received

THU-229	Blood donors in Europe have substantially higher risk of exposure to HEV than in North America: results from a systematic review and meta-analysis	Annika Wolski	Received

SAT-229	Outcomes of living liver donors are worse than those of matched healthy controls: nationwide cohort study	Jong Man Kim	Received

THU-230	A population based-study of rates and trends of hepatitis C in immigrants and the Canadian-born in Quebec, Canada, 1998-2018	Ana Maria Passos-Castilho	Received

FRI-230	Comparison between two 2D-SWE techniques using transient elastography as a reference method for liver stiffness assessment	Radu Cotrau	Received

SAT-230	Pretransplant changes in serum protein glycosylation relate to risk of HCC recurrence after liver transplantation and provide a potential prognostic biomarker: a proof-of-concept study	Xavier Verhelst	Received

THU-231	HBV screening in west african migrant community and faith-based organizations increases HBV vaccination among this high-risk population in greater Barcelona, Spain	Camila A Picchio	Received

FRI-231	Shear wave elastography is a useful and accurate tool to triage patients with acute liver failure syndromes	Francesca M Trovato	Received

SAT-231	Liver transplantation for complications of hepatoportal sclerosis	Andrew Keaveny	Received

THU-232	Community-based HBV testing among west african migrants in greater Barcelona, Spain increases linkage to specialist care and vaccination: the HBV-COMSAVA model	Camila A Picchio	Received

FRI-232	A novel simple and reliable 2D-shear wave elastography (SWE) and ultrasound-guided coefficient attenuation parameter (SCAP) technique for patients with chronic liver disease	Christiane Stern	Received

SAT-232	Discordance in categorization of acute-on-chronic-liver-failure in the national transplant database	Brian Lee	Received

THU-233	The impact of COVID-19 pandemic control measures on HCV treatment initiation in British Columbia, Canada	Naveed Janjua	Received

SAT-233	Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients	Valentina Cossiga	Received

SAT-234	A predictive model for mortality within one year of liver transplantation at the time of wait-listing for transplant: a novel approach using machine learning algorithms in a large US multi-ethnic cohort	Sripriya Balasubramanian	Received

THU-234	Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease	Carey Escheik	Received

FRI-234	Dynamics of liver stiffness predicts hepatocellular carcinoma and ascites occurrence in patients with hepatitis C virus related cirrhosis treated with direct-acting antiviral agents	Alberto Nicoletti	Received

THU-235	Associations of food insecurity and fast-food consumption with diet quality in adults with nonalcoholic fatty liver disease in a large population-based U.S. cohort	Ani Kardashian	Received

SAT-235	Monitoring patients with anti HBs trough levels can minimise hepatitis B immune globulin therapy after liver transplant	Erica Nicola Lynch	Received

FRI-235	The concordance within one blood test improves reliability evaluation of liver fibrosis	Paul Calès	Received

THU-236	Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy	Roberta DAmbrosio	Received

FRI-236	Novel and accurate measurement of differential protease activity in diagnosed HCC patients compared to non-HCC cirrhotic patients	Amit Singal	Received

SAT-236	Formal referral networks optimise patient ion for liver transplantation	Oliver Tavabie	Received

THU-237	Real life pooling of plasma samples for hepatitis C RNA detection as a screening strategy of hepatitis C active chronic infection	Federico Garcia Garcia	Received

SAT-237	Efficacy and safety of SARS-CoV-2 vaccination in liver transplant recipients	Lucy Meunier	Received

FRI-237	FIB-4 predicts severe hematological toxicity and 6-month mortality in older patients with cancer: ELCAPA-LIVER.	Victoire De Salins	Received

FRI-238	The main thing is to be alive - exploring patients experiences with weight gain after liver transplantation: a qualitative study	Sonja Beckmann	Received

SAT-238	Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study	Supachaya Sriphoosanaphan	Received

THU-238	Epidemiology of hepatocellular carcinoma in Portugal	Mario Jorge Silva	Received

SAT-239	Recurrence of primary sclerosing cholangitis after liver transplantation: a French cohort study including 571 patients	Florian Veyre	Received

THU-239	Zero C hospital project: an innovative screening and referral model in hospitalized patients at different divisions	valerio rosato	Received

FRI-239	Development of a nurse led hepatology ambulatory review service	Bryony Butler	Received

THU-240	LINK-B: a hepatitis B program to test and link to care patients lost of follow up	Anna Feliu-Prius	Received

FRI-240	Development of a nurse led daycase abdominal paracentesis service	Victoria Wharton	Received

THU-241	Testing for liver disease in primary case: fibrosis first	Ian Rowe	Received

SAT-241	Perinatal outcomes in liver transplant patients-possible positive effect of aspirin prophylaxis	Marius Braun	Received

FRI-241	Implementing a cirrhosis order set: a qualitative analysis of provider-identified barriers and facilitators	Ashley Hyde	Received

FRI-242	Quality of life in patients with advanced cirrhosis. Relationship with the development of complications	Ana Belén Rubio	Received

SAT-242	Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in liver transplant recipients	Aitor Odriozola Herrán	Received

THU-242	Hepatitis C care cascade analysis among adult women in Georgia	Ketevan Stvilia	Received

SAT-243	Early post liver transplant rescue treatment with sofosbuvir/velpatasvir/voxilaprevir in patients experienced to NS5A-inhibitors	Margherita Saracco	Received

THU-243	Progress in HCV screening in the national hepatitis C elimination program in Georgia during the COVID-19 pandemic, 2019-2021	Maia Tsreteli	Received

FRI-243	Effects of the COVID-19 pandemic on the activity of an advanced practice nurse clinic on liver cirrhosis	Martina Pérez-Guasch	Received

FRI-244	STIGMATIZATION IS COMMON IN PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE AND CORRELATES WITH QUALITY OF LIFE	Marta Carol Perdiguer	Received

SAT-244	Inclusion of body composition parameters in MELD score leads to optimization of predictive performance in patients with cirrhosis	Maryam Ebadi	Received

THU-244	Could a multi-target blood test make hepatocellular carcinoma surveillance programs more effective? A modelling-based virtual trial	Jagpreet Chhatwal	Received

FRI-245	Effect of e-health-based interventions on weight loss in patients with NAFLD: a systematic review and meta-analysis of randomized controlled trials	Ferya Celik	Received

SAT-245	Long-lasting seropositivity after anti SARS-CoV-2 vaccination in pre liver transplant patients	Alberto Calleri	Received

THU-246	A model, screen test and treat hepatitis C elimination project among under-served communities in Islamabad-the federal capital of Pakistan	Hassan Mahmood	Received

FRI-246	Role of mutant alpha-1-antitrypsin in determining liver cell fate during embryonic development and in HCC origin	Francesco Annunziata	Received

SAT-246	The outcome of living donor versus deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis	Beshoy Elkomos	Received

SAT-247	Impact of gender on survival of hepatocellular carcinoma	Chaonan Jin	Received

THU-247	Hepatitis B and hepatitis C testing practices and seroconversions among dialysis facilities in Georgia	Maia Butsashvili	Received

SAT-248	Effectiveness of MRI methods in the assessment of hepatic steatosis in living liver donors	Digdem Kuru z	Received

FRI-248	In vitro rescue of nonsense variations by drug-induced readthrough of premature termination codons in progressive familial intrahepatic cholestasis type 2	Martine LAPALUS	Received

THU-248	Innovative linkage model to re-engage loss-to-follow-up individuals in the national hepatitis C elimination program of Georgia	Vladimer Getia	Received

SAT-249	Long-term outcomes of donation after cardiac death and living donor liver transplant for primary sclerosing cholangitis	Dilip Moonka	Received

FRI-249	Search for biomarkers and prognostic indicators of liver degeneration in glycogen storage disease type Ia	Roberta Resaz	Received

THU-249	Combined COVID-19 vaccination and HIV and hepatitis C virus screening intervention for high-risk populations at a mobile testing unit in Madrid, Spain	Jeffrey Lazarus	Received

FRI-250	Alpha-1 antitrypsin (AAT) augmentation therapy and liver phenotype in individuals with homozygous PiZ AAT mutation (PiZZ genotype)	Malin Fromme	Received

SAT-250	Patients with acute-on-chronic liver failure have significantly greater healthcare resource utilization after liver transplantation	Vinay Sundaram	Received

THU-250	A model to eradicate HCV in undocumented migrants and low-income refugees in Italy	Nicola Coppola	Received

THU-251	Enhancing the cascade of hepatitis C care in community-recruited high-risk people who inject drugs during the COVID-19 pandemic: the Alexandros program	Angelos Hatzakis	Received

FRI-251	Impact of acute hepatic porphyria attack frequency on patient-reported outcomes: results from the porphyria worldwide patient experience research (POWER) study	Amy Dickey	Received

SAT-251	Use of statins after liver transplantation is associated with improved survival: results of a nationwide study	Chiara Becchetti	Received

THU-252	SVR4 and SVR12 monitoring by using dried blood spot test: is it the best alternative for people who use drugs?	Jeffrey Lazarus	Received

FRI-252	Large-scale, multi-centric prospective validation of the polycystic liver disease complaint-specific assessment (POLCA)	Antoon Billiet	Received

SAT-252	Liver transplantation for hepatocellular carcinoma with extended criteria: performance and applicability of the AFP score after official adoption by the French Organ Sharing Organization ABM: 5-year outcomes	Christophe Duvoux	Received

SAT-253	Tacrolimus drug exposure level in the first year after liver transplantation is an independant risk factor for de novo malignancy in patients transplanted for alcohol-related liver disease	Benedict Vanlerberghe	Received

THU-253	Collateral benefit of Georgia national hepatitis C elimination program - improving blood transfusion safety in the country of Georgia	Maia Alkhazashvili	Received

FRI-253	Improvements in quality of life in odevixibat responders and nonresponders: an analysis of pooled data from the PEDFIC 1 and PEDFIC 2 studies	Cara L. Mack	Received

FRI-254	Total, primary, and secondary serum bile acid changes and pruritus improvement during odevixibat treatment in patients with progressive familial intrahepatic cholestasis	Henkjan J. Verkade	Received

THU-254	Outcomes of a community led comprehensive HCV and HBV care provision model, including same-day test and treat to facilitate micro-elimination of HCV among people who inject drugs in Manipur, India	Rajkumar Nalinikanta	Received

SAT-254	SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine	Maciej K. Janik	Received

SAT-255	The effect of clinicopathologic findings of hepatocellular carcinoma on posttransplant survival: a multcenter cohort from TASL liver transplantation special interest group	Murat Akyildiz	Received

FRI-255	Changes in hepatic parameters, growth, sleep, and biochemical markers with odevixibat treatment across patients with various types of progressive familial intrahepatic cholestasis	Paris Fossa	Received

THU-255	A novel hepatitis C intervention in Denmark to test and treat people who inject drugs	Jeffrey Lazarus	Received

FRI-256	Analysis of quality of life, hepatic biochemical markers, and sleep in patients with progressive familial intrahepatic cholestasis who had a pruritus response with odevixibat treatment	Paris Fossa	Received

SAT-256	Utility and prognostic value of diagnosing metabolic dysfunction-associated fatty liver disease in patients undergoing liver transplantation for alcohol-related liver disease	Benedict Vanlerberghe	Received

THU-256	Peer-led hepatitis C services reach poorly served populations at scale: a model for tackling health inequalities	Leila Reid	Received

FRI-257	Longitudinal follow-up data on adults with classic, severe alpha-1 antitrypsin deficiency (PiZZ genotype)	Malin Fromme	Received

THU-257	Cost-effectiveness of integrated treatment for hepatitis C virus among people who inject drugs in Norway: an economic evaluation of the INTRO-HCV trial	Aaron G. Lim	Received

SAT-257	Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Corovavirus Disease-2019 (COVID-19) convalescence after liver transplantation - a prospective six month follow up	Theresa Kirchner	Received

FRI-258	Gender dependent neurological and hepatic improvement in Wilson disease patients treated with Trientine dihydrochloride: post hoc results from a prospective study	Larissa Wijnberg	Received

SAT-258	A third dose of the BNT162b2 mRNA vaccine significantly improved immune response among liver transplant recipients	Yana Davidov	Received

THU-258	Characterization of HCV recent infections and re-infections among high-risk population from Georgia using global hepatitis outbreak and surveillance technology	Adam Kotorashvili	Received

FRI-259	Efficacy and safety of odevixibat over 72 weeks of treatment in patients with progressive familial intrahepatic cholestasis	Richard J. Thompson	Received

SAT-259	Everolimus combined with low-dose tacrolimus controls histological graft injury and liver fibrosis as sufficiently as high-dose tacrolimus combined with mycophenolate after liver transplantation	Fabian Dranicki	Received

THU-259	Prevalence and predictors of significant liver fibrosis : a population-based cross-sectional study	Aayushi Rastogi	Received

FRI-260	In vitro rescue of the bile acid transport function of some ABCB11 variants by CFTR potentiators: a targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2	Elodie Mareux	Received

SAT-260	The portrait of adult liver transplant recipients in the United States from 2002-2020	Carey Escheik	Received

THU-261	Prognostic value of liver function test for COVID-19 hospitalized patients with respiratory disease	Carlos Alventosa Mateu	Received

FRI-261	Plasma-based proteomics profiling of patients with Wilsons disease	Jie Su	Received

SAT-261	Heterologous regimen viral-vector/mRNA produces significantly higher SARS-CoV-2 humoral response than homologous viral-vector and inactivated vaccines in liver transplant recipients	Manuel Mendizabal	Received

THU-262	Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis	Binu John	Received

SAT-262	Evolution of pretransplant cardiac risk factor burden and major adverse cardiovascular events in liver transplant recipients over time	Claire Harrington	Received

FRI-262	Management of hepatic sarcoidosis - multicentric approach	Janina Sollors	Received

SAT-263	Retransplantation (reLT) outcomes of patients who were initially transplanted for ACLF	gandhi lanke	Received

THU-263	Humoral, cellular, clinical responses and safety to SARS-CoV-2 messanger RNA vaccines in patients with compensated and decompensated cirrhosis: a long-term single center prospective study	massimo iavarone	Received

FRI-263	Plasma proteomics identifies hepatic steatosis and sex differences in 2,147 children and adolescents	Lili Niu	Received

FRI-264	Pregnancy outcomes in women with Budd Chiari syndrome: a single center experience	Sagnik Biswas	Received

SAT-264	The ratio of Activin A and Follistatin-related gene allows prediction of posthepatectomy liver failure and postoperative morbidity in patients prior to liver surgery	Jonas Santol	Received

THU-264	The protective role of dairy protein on sarcopenic obesity in middle-aged and older women: a community-based, 12-year, prospective cohort study	Jun-Hyuk Lee	Received

THU-265	Detection of microplastics in cirrhotic liver tissue	Thomas Horvatits	Received

FRI-265	New cases of Budd-Chiari syndrome and splanchnic vein thrombosis after COVID-19 vaccination - a vascular liver disease group (VALDIG) initiative	Raoel Maan	Received

SAT-265	Derivation of a cardiac risk index for use in liver transplantation for non-alcoholic steatohepatitis	Paul Levy	Received

THU-266	Patient Navigators: an innovative approach to improve hepatitis c case finding leveraging existing human immunodeficiency virus service delivery models to reach last mile patients in Nasarawa State, Nigeria	Chukwuemeka Agwuocha	Received

FRI-266	Abdominal wall hernia is a frequent complication of polycystic liver disease and associated with hepatomegaly	Thijs Barten	Received

SAT-266	The prognostic effect of adequate lymphadenectomy in clinically node-negative patients undergoing liver resection for intrahepatic cholangiocarcinoma	Carlo Sposito	Received

THU-267	The Community Pop-Up Clinic (CPC): a unique strategy to achieve HCV elimination in the inner city	Brian Conway	Received

FRI-267	MR-derived metrics have utility in identifying paediatric patients with stable autoimmune hepatitis	Piotr Pawliszak	Received

SAT-267	Impact of MELD 3.0 versus MELD-Na in patients with renal dysfunction	Allison Kwong	Received

SAT-268	Sustainability of humoral immunity induced by the SARS-CoV-2 vaccine and response to booster dose among Liver Transplant recipients	Liane Rabinowich	Received

FRI-268	Development and validation of a novel ICP-MS method to quantify different copper species in human plasma from patients with Wilson disease	Ryan Pelto	Received

THU-268	Age, gender and region-specific HBsAg and anti-HCV seroprevalence in Ghana: a nationwide hospital based cross-sectional study	Yvonne Ayerki Nartey	Received

THU-269	The elimination of hepatitis C in the cherokee Nation: the impact of harm reduction	Devin Razavi-Shearer	Received

SAT-269	Acute-on-chronic liver failure due to severe intrahepatic vaso-occlusion and recurrence of the intial disease: 2 major features in liver transplantation for severe sickle-cell-related hepatopathy	Christophe Duvoux	Received

FRI-269	Quantitative magnetic resonance cholangiopancreatography identifies features of ductal disease change in primary sclerosing cholangitis: a prospective observational cohort study	Liam Young	Received

SAT-270	Post-operative complications and short-term survival in obese cirrhotic patients undergoing liver transplantation	Carmen Alonso Martin	Received

FRI-270	Age at diagnosis is associated with mortality in patients with hereditary hemochromatosis	Clare Foley	Received

THU-270	Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant	Binu John	Received

THU-271	Epidemiology and management of hepatitis B and C in primary care in the Netherlands - data from the Rijnmond primary care database	Sylvia Brakenhoff	Received

FRI-271	Development of Hepatoblastoma organoids as a patient-derived ex-vivo system	Laura Zanatto	Received

SAT-271	Impact of comorbidities on liver transplantation: a prospective and multicentric study	Magdalena Salcedo	Received

THU-272	Point of care testing for hepatitis C in the priority settings of mental health, prisons and drug and alcohol facilities	Catherine Ferguson	Received

FRI-272	High rates of histological findings compatible with porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels undergoing a liver biopsy	Nicola Pugliese	Received

SAT-272	Liver transplant patients infection rate with SARS-CoV-2 is lower but depend upon the infection rate in the general population and have a better outcome	Michal Cohen-Naftaly	Received

FRI-273	Plasma metabolomics and machine learning characterizes metabolite signature capable of segregating patients with poor outcome in pediatric cirrhosis	Babu Mathew	Received

THU-273	Association of novel lifestyle- and whole foods base inflammation scores with metabolic dysfunction-associated fatty liver disease: a population-based study among iranian adults	Ehsaneh Taheri	Received

SAT-273	Sarcopenia predict complications after hepatic resection for primary hepatocellular carcinoma (HCC) in patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH)	Federico Ravaioli	Received

SAT-274	A comparison of hispanic living liver donor candidates approved and denied at a high-volume urban transplant center	Dana Toy	Received

FRI-274	Experience of cholestatic pruritus emphasized by patients with PBC: results from the PBC Foundation app survey	Chris Mitchell	Received

THU-274	Assessment of COVID-19 impact and response on hepatitis B virus and hepatitis C virus prevention and treatment from nationwide survey in Japan	Md Razeen Ashraf Hussain	Received

FRI-275	Cancer risk in acute hepatic porphyria: a nationwide matched cohort study in 1,245 individuals	Hannes Hagstrm	Received

THU-275	Knowledge, attitude and practice regarding COVID-19 vaccination among HCV infected patients in Georgia	Lasha Gulbiani	Received

SAT-275	Liver transplantation in HIV infected subjects: a long-term single center experience	Noemi Gualandi	Received

SAT-276	SARS-CoV-2 infection in liver transplant recipients - a single center case series from Romania	Ioana-Alexandra Husar-Sburlan	Received

FRI-276	Innovative approach using clinical metagenomics for the diagnosis of non-elucidated liver disease	Anna Sessa	Received

THU-276	CRIVALVIR-FOCUS: low HIV and chronic Hepatitis B and C infection prevalence among women in reproductive and sexual health services in Valencia, Spain	Miguel Garcia Deltoro	Received

FRI-277	Accumulation of molybdenum in major organs following chronic oral administration of bis-choline tetrathiomolybdate in Sprague Dawley rats	Kharmen Billimoria	Received

THU-277	mRNA COVID-19 vaccine effectiveness in liver transplant patients	Muhammad Khan	Received

SAT-277	Liver transplantation for hepatocellular carcinoma: outcome and prognostic factors for recurrence	Veronica Paon	Received

SAT-278	The liver outcomes and equity (LOEq) index: neighborhood social determinants independently predict outcomes in liver transplantation	Kali Zhou	Received

THU-278	Evaluation of global progress towards HBV and HCV elimination	Sarah Blach	Received

THU-279	The Impact of Vaccination on the Global and Regional Pediatric Prevalence of Hepatitis B from 1985-2022	Devin Razavi-Shearer	Received

FRI-279	Liver fibrosis and fat by transient elastography in patients with Alpha-1 antitrypsin deficiency	Hassaan Yousuf	Received

SAT-279	Prevalence, prognosis, clinical, biological and histological features of incidentally found hepatocellular carcinoma after liver transplantation	bénédicte delire	Received

THU-280	Feasibility and effectiveness of hepatitis C micro-elimination among 19 prisons of northern India	Kanudeep kaur	Received

FRI-280	Novel imaging feature in patients with porto-sinusoidal vascular disorder (PSVD) - radiological evaluation guiding diagnosis	Georg Semmler	Received

SAT-281	Long-term outcomes of liver transplantation (LT) using grafts from donors with active and chronic hepatitis B virus (HBV) infection: multi-center cohort study	Sujin Gang	Received

THU-281	The impact of treatment and health policies for Hepatitis C Virus on hospitalizations in the last decade: data analysis of records of hospital discharge (SDO) at Italian national level	Claudia Simonelli	Received

SAT-282	Safe use of hepatitis B surface antigen positive (HBsAg ()) grafts in liver transplantation (LT): a nationwide study based on KOTRY (Korean Organ Transplantation Registry) data	Sujin Gang	Received

THU-282	Hepatitis B birth dose coverage remains dramatically low in The Gambia and has been disrupted by the COVID-19 pandemic	Maud Lemoine	Received

FRI-282	The role of the mechanistic target of rapamycin (mTOR) in Alpha-1 Antitrypsin Deficiency	Lisa Bewersdorf	Received

FRI-283	Cerebrotendinous xanthomatosis: long-term course in 5 patients and first description of a successful pregnancy management during therapy with chenodesoxycholic acid (CDCA)	Jan Koehler	Received

SAT-283	A panel of three micro RNAs allows robust prediction of overall survival after liver resection	David Pereyra	Received

THU-283	Hepatitis B prevalence and the impact of vaccination in Georgia: results from a nationwide serosurvey	Nino Khetsuriani	Received

FRI-284	A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population	Anne-Sofie Seidelin	Received

THU-284	Progress towards HCV elimination in the country of Georgia: Insights from modelling and national survey	Josephine Walker	Received

SAT-284	Liver transplantation for primary sclerosing cholangitis and predictors of disease recurrence	Julie Zhu	Received

FRI-285	A small molecule chaperone for alpha-1 antitrypsin deficiency-associated liver disease reduces liver polymer burden in the PiZ mouse model	Britta Handyside	Received

SAT-285	Predictive factors of antibody response after anti-SARS-CoV-2 vaccine in liver transplant recipients	Ilias Kounis	Received

THU-285	Measuring the alcohol related hospital burden in Ireland and the impact of Minimum Unit Pricing (MUP)	Tobias Maharaj	Received

SAT-286	Immunotherapy before solid organ transplantation: an international transplant community-focused survey	Tommy Ivanics	Received

THU-286	Is hepatic steatosis individually a risk factor for colorectal adenoma?	Anuroop Yekula	Received

FRI-286	A melting pot of genetic variability in Wilsons disease - real world study from London, UK	James Liu Yin	Received

FRI-287	The alpha-1 antitrypsin PiZ allele is an independent risk factor for liver transplantation/death in patients with advanced chronic liver disease	Lorenz Balcar	Received

SAT-287	Evaluating the predictive performance and transferability of machine learning-based prediction models using national liver transplant data registries	Tommy Ivanics	Received

THU-287	No effect of HBsAg positivity on antibody response after COVID-19 vaccine	Ganbolor Jargalsaikhan	Received

FRI-288	Fontan associated liver disease: A cohort review into the prevalence of portal hypertension	Hannah Donnelly	Received

SAT-288	Liver transplant recipients have a higher incidence of lung cancer than general population	Jose Ignacio Herrero	Received

FRI-289	Senolytic therapies have a place in pediatric biliary cirrhosis	Giulia Jannone	Received

THU-289	Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years	Raquel Domínguez-Hernández	Received

SAT-289	Survival benefit-based priority of liver transplantation in HBV-related acute-on-chronic liver failure	Jun Li	Received

FRI-290	PNPLA3 rs738409 G allele increases the risk of liver cirrhosis in SERPINA1 MZ heterogygotes	So&328;a Fra&328;ková	Received

SAT-290	Social determinants of health and racial disparities in liver transplant: a nation wide analysis	Mahmoud Mansour	Received

THU-290	The value of increased HCV testing and treatment strategies in Spain to achieve elimination goals	Alon Yehoshua	Received

SAT-291	Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients	Yana Davidov	Received

FRI-291	Patient experience of their Primary Biliary Cholangitis (PBC) management compared to clinical practice guidelines	Chris Mitchell	Received

THU-291	National Hepatitis Elimination Profiles: Progress towards HBV and HCV elimination in five European countries	Lindsey Hiebert	Received

THU-292	Economic investment and strategies to eliminate hepatitis C in Mexico	Ellen Mooneyhan	Received

FRI-292	Evaluation of the clinical impact of the Ceruloplasmin variant p.Thr551Ile in liver cirrhosis	Marlene Panzer	Received

FRI-293	Circulating miR-21 parallels the incidence of IBD in PSC patients	André Santos	Received

SAT-293	Hepatic evaluation of patients with telomeropathies	Olivia Portolese	Received

SAT-294	Third dose of SARS-COV2 mRNA-vaccine in liver transplant recipients: can it bridge the response gap?	Raffaella Lionetti	Received

FRI-294	Hepatocellular Carcinoma in Fontan Associated Liver Disease: Uncharted Territory - Are We Doing Enough?	Michael Christmas	Received

THU-294	Eliminating chronic hepatitis B in the Northern Territory of Australia through a holistic care package delivered in partnership with the community	Jane Davies	Received

SAT-295	Protein-energy malnutrition is associated with worse outcomes in patients admitted for liver transplant: analysis of national inpatient sample	Mahmoud Mansour	Received

THU-295	Hepatitis C prevalence and elimination in Pakistan; a bottom-up approach accounting for provincial variation	Ellen Mooneyhan	Received

FRI-295	Are patients with Fontan-associated liver disease (FALD) appropriately screened for oesophageal varices? Queensland Quaternary adult congenital heart disease referral centre experience	Anthony Bergin	Received

FRI-296	Primary liver malignancies in patients with Wilsons disease	Rodolphe SOBESKY	Received

SAT-296	COVID Vaccination among Liver Transplant Recipients: A EASL - ESOT/ELITA - ILTS multi society survey	Carmen Vinaixa	Received

THU-296	Association between immunosuppressants and poor antibody responses to inactivated SARS-CoV-2 vaccines in patients with autoimmune liver diseases	hu li	Received

THU-297	Like what? You think I have that? - Impact of stigma on pharmacy-based identification and treatment of hepatitis C in Victoria, British Columbia	Kellie Guarasci	Received

FRI-297	Defining the boundaries for stability in Wilson disease patients on maintenance chelation therapy: Lessons from the CHELATE Trial	Michael Schilsky	Received

SAT-297	Does m-RNA Vaccination protect from Sars-Cov2 (asymptomatic) infection in liver transplant recipients?	Ubaldo Visco Comandini	Received

THU-298	Improved clinical and economic outcomes in an intensive care unit with a focus on hepatology through interprofessional cooperation between physicians, staff nurses, and pharmacists	Schmid Stephan	Received

SAT-298	Low dose interleukin-2 ively expands circulating regulatory T cells but fails to promote transplantation tolerance in humans	Tiong Yeng Lim	Received

FRI-298	Precision-cut liver slices as an ex vivo model to assess impaired hepatic glucose production	Kishore Alagere Krishnamurthy	Received

FRI-299	Interim 52-week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A	Britta Handyside	Received

THU-299	Need to implement the screening strategy to advance HCV elimination in Italy: a cost-consequences analysis	Kristi Tata	Received

SAT-299	Clinical significance of three-dimensional printing of the portal venous system in patients with extrahepatic portal hypertension	Binita Chaudhary	Received

THU-300	Evaluation of access to treatment for Hepatitis C: a large retrospective cohort from a tertiary care hospital in Turkey	Merve Eren Durmus	Received

SAT-300	Liver Transplantation (LT) and Ethnicity in the United States: The Impact of Non-alcoholic Steatohepatitis	Carey Escheik	Received

SAT-301	CAN ENDOTHELIAL BIOMARKERS BEFORE LIVER TRANSPLANTATION TOGETHER WITH CLASICAL CARDIOVASCULAR RISK FACTORS BE USEFUL TO PREDICT CARDIOVASCULAR RISK AFTER LIVER TRANSPLANTATION	Victoria Aguilera	Received

THU-301	Hepatitis E Virus Capsid Antigen (HEV-Ag): a practical diagnostic biomarker in the HEV outbreak scenerio	Simon Lytton	Received

FRI-302	Active case management to connect hepatitis C notifications to care and treatment in Australia (CONNECT study), a randomised controlled trial	Tafireyi Marukutira	Received

SAT-302	Factors contributing to late evaluation in liver transplant candidates undergoing inpatient liver transplant evaluation	Katherine Cooper	Received

THU-302	Bulevirtide is broadly active against all HDV genotypes expressing envelopes from HBV genotypes A-H and a large panel of clinical isolates	Savrina Manhas	Received

FRI-303	Find out HCV patients: systematic study of 2013-2020 HCV files of a MDT viral hepatitis expert unit on the future of patients has made it possible to find out the lost ones and put them into treatment	ANDRE JEAN REMY	Received

SAT-303	CMV REACTIVATION IS ASSOCIATED WITH LOWER HEPATOCELLULAR CARCINOMA (HCC) RECURRENCE AFTER LIVER TRANSPLANTATION (LT)	Victoria Aguilera Sancho	Received

THU-304	Functionnal and mitochondrial dynamics alterations in patients with chronic hepatitis B and advanced fibrosis	Dimitri Loureiro	Received

SAT-304	Managing HBV/HDV co-infection post liver transplant - Exploring a decade of experience	Almuthana Mohamed	Received

FRI-304	Effectiveness of a central monitoring system for the continuum of care of hepatitis C in Brazil during COVID-19 pandemic	Paulo Bittencourt	Received

FRI-305	Retrieval of HCV patients lost to follow-up as a strategy as a strategy for hepatitis C microelimination: results of a brazilian multicentric study	Paulo Bittencourt	Received

THU-305	Dual antiviral activity of farnesyl transferase inhibitor on hepatitis D virus infection revealed by RT-ddPCR	Eloi Verrier	Received

SAT-305	Durability of SARS-CoV-2 specific immune response following different primary prime-boost vaccine platforms and subsequent humoral response to booster dose among liver transplant recipients	Supachaya Sriphoosanaphan	Received

FRI-306	Reorganizing and simplifying HCV diagnosis and treatment in special populations during COVID pandemic and beyond	Paolo Scivetti	Received

THU-306	Characterization of circulating hepatitis B Virus RNAs in vitro and chronic hepatitis B patients	Doohyun Kim	Received

SAT-306	Outcome of choledochal cysts with intrahepatic involvement (type IV-A) after extrahepatic cyst excision and roux-en-Y hepaticojejunostomy in adults	Utpal Anand	Received

SAT-307	The impact of COVID-19 on the duration of the liver transplant process in patients presenting for inpatient liver transplant evaluation	Katherine Cooper	Received

THU-307	Identification of shuttle protein hnRNPA1 as a modulating factor of circulating hepatitis B Virus RNAs release in chronic hepatitis B patients	Hyoseon Tak	Received

FRI-307	The health economic outcomes of trial ACTG5360/MINMON	Tannishtha Pramanick	Received

THU-308	Long-read sequencing of HCC samples reveals complete architecture of HBV integrations and chimeric mRNA isoforms associated with oncogenes	Cameron Soulette	Received

SAT-308	Patients with polcystic liver disease have longer waiting times but better clinical outcomes following liver transplantation in the UK	Matthew Gittus	Received

FRI-308	Hepatitis C treatment during the COVID-19 pandemic has similar efficacy with less resource utilization: analysis from the British Columbia HCV network	Alnoor Ramji	Received

FRI-309	ELIMINATE - interim results of an Austrian HCV macro-elimination project	Caroline Schwarz	Received

THU-309	Polymorphic analysis of bulevirtide sequence in PreS1 of large HBsAg across HBV genotypes A-H	Roberto Mateo	Received

SAT-309	Missed referrals for liver transplant evaluation are associated with worse outcomes in patients needing inpatient liver transplant evaluation	Katherine Cooper	Received

FRI-310	The korean hepatitis C virus care cascade in a tertiary institution: current status and changes in testing, link to care, and treatment	Jonggi Choi	Received

SAT-310	Nutritional intake after liver transplant: systematic review with meta-analysis and meta-regression	Lynsey Spillman	Received

SAT-311	Impact of muscle mass on survival of patients with Hepatocellular Carcinoma after liver transplantation beyond the Milan criteria	Berend Beumer	Received

THU-311	Limited value of HBV-RNA levels for the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in HBe antigen negative chronic hepatitis B patients	Valerie Ohlendorf	Received

FRI-311	Macroeconomic assessment of overall and per-patient healthcare costs of Hepatitis C-infected patients in an integrated health system in the era of direct-acting antiviral therapy	David Kaplan	Received

THU-312	A versatile small animal immunocompromised model for chronic hepatitis E	Siddharth Sridhar	Received

FRI-312	Awareness of chronic hepatitis B and C among men who have sex with men (MSM): epidemiological survey and on-site screening	Marie Coessens	Received

FRI-313	Predictive factors for lost to follow-up pre and post-hepatitis C treatment: data from the British Columbia hepatitis C virus network	Alnoor Ramji	Received

THU-313	Acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg stability and secretion and promotes cell survival	Lorenzo Piermatteo	Received

SAT-313	Evaluation of predictive factors for postoperative nausea and vomiting in hepatobiliary cancer patients	Luciano Beltrão Pereira	Received

SAT-314	Immune responses before and after liver transplantation: a cohort study of the induced immune response	Dina Leth Mller	Received

FRI-314	HCV screening in a tertiary french hospital : just do it	Si Nafa Si Ahmed	Received

THU-314	PAGE-B and FIB-4 predict the occurence of hepatocellular carcinoma in HBV patients: a french nationwide cohort study	GAUTIER BOILLET	Received

SAT-315	Andrographolide can potentially rescue unusable liver grafts by reducing fat content, enhancing mitochondrial function, and inhibiting Th1/Th17 immunity	Tengfei Si	Received

THU-315	High tolerance of hepatitis E virus towards alcohol-based disinfectants	Patrick Behrendt	Received

THU-316	Multicentre performance evaluation of the Elecsys HCV Duo immunoassay	Sam Bunting	Received

FRI-316	Maximizing the potential of Cepheid, GeneXpert PCR rapid testing for hepatitis C through use of finger prick blood samples collected into EDTA capillary tubes	Anam Choudhry	Received

SAT-316	Trends and causes of etiology in adult liver transplant patients: multicenter study	Mesut Akarsu	Received

FRI-317	Healthcare resource utilization in treatment-nave patients with compensated cirrhosis receiving 8-weeks glecaprevir/pibrentasvir stratified by drug use and socioeconomic status: a retrospective chart review	Sean Littlewood	Received

THU-317	Intrahepatic transcriptional profiling demonstrates preclinical models of chronic hepatitis B resemble different stages of natural history in humans	Ricardo Ramirez	Received

SAT-317	A new avatar mouse model to predict the liver immune homeostasis and histologic inflammation of liver transplant patients	Soon Kyu Lee	Received

THU-318	Hepatitis B virus splice variants are associated with reduced likelihood of functional cure and differ across phases of chronic hepatitis B infection	Peter Revill	Received

SAT-318	Hepatocellular carcinoma and the risk of cancer onset after liver transplantation - role of immune activation and aging profiles	Sarah Shalaby	Received

FRI-319	Screening for hepatitis C in Denmark - the effect of a mobile outreach intervention	Sandra Drse	Received

SAT-319	The crucial role of PARP poly(ADP-ribose polymerase on the post-ischemic liver injury and inflammation	Michitaka Ozaki	Received

THU-319	Understanding acute HCV infection kinetics in humanized mice via an agent-based modeling approach	Harel Dahari	Received

THU-320	Presence of sodium taurocholate co-transporting polypeptide and hepatitis B replication markers on placenta: another home for the virus?	Ashish Kumar Vyas	Received

FRI-320	Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region	Pietro Torre	Received

SAT-320	Mitochondrial transplantation attenuates murine in vivo hepatic ischemia/reperfusion injury	Avinash Mukkala	Received

THU-321	Exploring dynamic changes in HBcrAg and HBV RNA in e-Antigen negative HBV/HIV patients on antiretroviral therapy: still evidence of integrated activity after 5 years of treatment	Ruth Byrne	Received

FRI-321	Treating children with HCV close to home through a virtual national multidisciplinary network	Deirdre Kelly	Received

FRI-322	Association of sustained virologic response with measures of direct-acting antiviral adherence in patients with hepatitis C: data from the ASCEND and ANCHOR investigations	Sarah Kattakuzhy	Received

THU-322	Next-generation sequencing of Swiss HEV isolates allows for reconstitution of functional clones	Jérme Gouttenoire	Received

FRI-323	ATA haplotype of the interleukin-10 gene and low phase angle are associated with liver cirrhosis in chronic hepatitis C	Nataly Lopes Viana	Received

FRI-324	Use of Glecaprevir/Pibrentasvir (G/P) for the treatment of HCV infection among fentanyl users: an interim analysis of the GRAND PLAN study	Brian Conway	Received

THU-324	Combined effect of Vonafexor and Interferon-alpha on HBV replication in primary human hepatocytes	David Durantel	Received

THU-325	Hepatitis Delta virus quasispecies conservation and variability in ribozyme region	Beatriz Pacín Ruiz	Received

FRI-325	Indigenous methodologies in practice through community engagement and telehealth outreach increase hepatitis C access to care in Alberta, Canada	Sam Lee	Received

THU-326	Exosomal cargo as a key player of the immune response after direct-acting antiviral treatment in chronic hepatitis C patients	Ioannis-Georgios Koskinas	Received

FRI-326	Implication of metabolic associated fatty liver disease and sex differences in the risk of developing liver fibrosis in patients with Hepatitis C	Martín Uriel Vázquez Medina	Received

FRI-327	Micro-eliminating hepatitis C in a network of 47 English Prisons through an industry, prison healthcare and patient organisation partnership	Andy Jones	Received

THU-327	Therapeutic suppression of HBV transcripts promotes reappearance of the SMC5/6 complex and cccDNA silencing in vivo without affecting posttranslational modifications of cccDNA-bound histones	Lena Allweiss	Received

THU-328	Updated national prevalence estimates of chronic hepatitis B virus infection in countries within the European (EU) and European Economic Area (EEA): a systematic review	Sandra Bivegete	Received

FRI-328	The Viennese epidemic of acute HCV in the era of direct-acting antivirals	David JM BAUER	Received

THU-329	Relevance of HEV detection in ejaculate of chronically infected patients	Mathias Schemmerer	Received

FRI-329	Approaches for a hepatitis C-free city: preliminary results	Manuel Romero Gomez	Received

THU-330	HDV-mediated inhibition of HBV in superinfection mouse model: the role of type I Interferon	Beatriz Pacín Ruiz	Received

FRI-331	Impact of hepatitis C virus point-of-care (PoC) viral load assay compared to laboratory-based assays on uptake of testing and treatment, and turnaround times: a systematic review and meta-analysis	Adam Trickey	Received

THU-331	Assessment of Myrcludex or heparin antiviral activity on HBV infection using a 3-dimensional primary human hepatocyte culture system	Juliette Besombes	Received

FRI-332	Diagnostic accuracy of point-of-care HCV viral load assays for HCV diagnosis: a systermatic review and meta-analysis	Weiming Tang	Received

THU-332	Concordance of the Xpert hepatitis B viral load test and conventional quantitative PCR in detecting and quantifying viremia using stored plasma and dried blood spot samples in West Africa	Gibril Ndow	Received

FRI-333	Hepatitis-C virus viral load reflex testing following an innitial positive HCV antibody test: a global systematic review and meta-analysis	Weiming Tang	Received

THU-333	A high-throughput viral integration sequencing method reveals that mitochondrial DNA is frequently targeted by HBV integration	Teresa Pollicino	Received

THU-334	Enhanced T cell responses in patients and mouse model of hepatitis B and comorbid non-alcoholic fatty liver disease	Nishi Patel	Received

FRI-334	Finding cases of hepatitis C for treatment using automated screening in the emergency department is effective, but what is the cost?	David Prince	Received

THU-335	Hepatitis B virus sero-prevalence and genotype distribution among pregnant women in Siem Reap, Cambodia	Bunthen E	Received

FRI-335	A cluster randomized controlled study of secondary distribution of HCV self-test to support micro-elimination in Karachi, Pakistan.	Saeed Hamid	Received

THU-336	Genotype distribution and mutations associated with hepatocellular carcinoma risk among hepatitis B carriers in Goto Islands, Japan	Serge Ouoba	Received

THU-337	Comprehensive analysis of the different phases of chronic hepatitis B virus infection	Michael Basic	Received

FRI-337	From extensive to intensive screening, co-operations model of hepatitis C elimination in out-patients and people who inject drug population in southwest of China	Qing Lin	Received

FRI-338	Using time to positivity of hepatitis rapid detection test results to determine active viremia	Saeed Hamid	Received

THU-338	Human stem cell-derived hepatic and intestinal culture systems to study HEV transmission along the gut-liver axis	Sarah PRALLET	Received

THU-339	A novel class of glycan-specific human monoclonal antibodies neutralizing the Hepatitis E Virus	Katja Dinkelborg	Received

FRI-339	Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets	Syed Hassan Bin Usman Shah	Received

FRI-340	Identifying risk factors associated with hepatitis C virus infection in participants in the National Health and Nutrition Examination Survey using Super Learner	Laura Telep	Received

THU-340	Increased lymphocyte trafficking and myeloid activation in patients with chronic hepatitis delta	Ester García-Pras	Received

THU-341	Discordant serum HBV DNA and RNA correlation with quantitative HBsAg and high levels of intrahepatic integrated HBV DNA in HBeAg negative chronic hepatitis B	Daryl Lau	Received

SAT-341	Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience	Katja Deterding	Received

SAT-342	Challenges with the cascade of HDV care in Mongolia	Nandintsetseg Tsoggerel	Received

THU-342	Hepatitis B virus-replicating transgenic mice exhibit a functional but restricted responsiveness to exogenous Tlr3 and Rig-I stimuli	Stefan Schefczyk	Received

THU-343	Profiling at single hepatocyte level indicates variance in viral replication associated with HBeAg status in chronic hepatitis B patients	Marianne Tuefferd	Received

SAT-343	Safety, tolerability and pharmacokinetics of single ascending doses of ALG-020572, a GalNAc-conjugated antisense oligonucleotide, in healthy subjects	Min Wu	Received

FRI-343	Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis	Ian Lockart	Received

SAT-344	Predictors of HBsAg loss after cessation of nucleo(s)tide analogue therapy in asian patients with low HBsAg levels	Milan Sonneveld	Received

FRI-344	Glycomics-based serum marker as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection	Nicky Somers	Received

THU-344	Human stem cell-derived hepatocytes as a model for hepatitis D virus infection	Huanting Chi	Received

THU-345	Hepatitis B viral load variation between the first and third trimesters of pregnancy	Stuart Gallacher	Received

SAT-345	Improvement of liver-stiffness after 6 months of therapy: real-life data for HBV/HDV co-infected patients treated with bulevirtide	Alexander Killer	Received

FRI-345	Post-treatment elevated gamma-glutamyl transferase is the best predictor for future outcomes in HCV patients achieving sustained virological response - data from the german hepatitis C-registry (DHC-R)	Stefan Mauss	Received

FRI-346	The impact of liver function improvement after direct-acting antiviral therapy on the outcome in hepatitis C virus patients with decompensated cirrhosis	Yuki Tahata	Received

THU-346	Greater sequence diversity during early hepatitis B virus decline on vebicorvir plus entecavir is associated with a lower level of virus rebound following switch to entecavir monotherapy	Kathryn M Kitrinos	Received

SAT-347	Model to predict on-treatment restoration of functional HBV-specific CD8 cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B	Julia Peña Asensio	Received

FRI-347	De-novo occurrence of portal vein thrombosis in patients with HCV-related cirrhosis after sustained virological response: medium to long term observations from the ongoing PITER cohort	Loreta Kondili	Received

THU-347	Results from a nationwide hepatitis C serosurvey and progress towards HCV elimination in the country of Georgia	Maia Tsereteli	Received

THU-348	Clinical impact of drug interaction in the use of antipsychotics by HCV patients treated with pangenotypic direct-acting antivirals	Marinela Mendez	Received

SAT-348	Antiviral treatment cessation in HBeAg negative chronic hepatitis B: clinical outcome is associated with increase in specific pro-inflammatory cytokines	Marte Holmberg	Received

FRI-348	Suboptimal follow-up, high re-infection, and drug-related death, among HCV-treated people who inject drugs in Tayside, Scotland	Christopher Byrne	Received

FRI-349	Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study	Joanne Carson	Received

THU-349	Occult hepatitis C infection detection in people who use drugs with or without direct antiviral agents therapy	Eliane Silva	Received

SAT-349	Tenofovir alafenamide for pregnant chinese women with active chronic hepatitis B: a multicenter, prospective, real-world study	Qing-Lei Zeng	Received

FRI-350	Five-years follow-up of cured HCV patients with or without cirrhosis under real-world interferon-free therapy	Robert Flisiak	Received

THU-350	Strong correlation between HBsAg, ALT and HDV-RNA levels in patients with chronic hepatitis D. Results of phase 3 D-LIVR study.	Maria Buti	Received

SAT-350	Suboptimal virological response to antiviral therapy in chronic hepatitis B as an independent predictor for occurrence of HCC and development of severe liver events	Chau-Ting Yeh	Received

THU-351	Detection of highly variable RNA-containing viral particles on CNT-based electrochemical impedimetric DNA-nanosensors	Victor Hryharovich	Received

SAT-351	Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta	Dmitry Manuilov	Received

SAT-352	Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta	Dmitry Manuilov	Received

FRI-352	Reverse Inflamaging: biological age is accelerated in chronic HCV patients and decelerates after HCV cure	Carlos Oltmanns	Received

THU-352	Hepatitis B Delta: assesment of knowledge and practices of French non academic hepato-gastroenterologists	Jean-Franois Cadranel	Received

FRI-353	Overall mortality in patients with chronic hepatitis C: major effects of social vulnerability, tobacco smoking, and history of unhealthy alcohol use (ANRS CO22 HEPATHER cohort)	Hélène Fontaine	Received

SAT-353	Virologic response to bulevirtide is delayed in cirrhotic HDV patients with clinically significant portal hypertension	Mathias Jachs	Received

THU-353	Hepatitis E seroprevalence in solid organ transplant recipients in Croatia	Anna Mrzljak	Received

FRI-354	Is routine Ribavirin mandatory for genotype 3 hepatitis C compensated cirrhosis patients receiving Sofosbuvir/Velpatasvir? A meta-analysis	Jing Hong Loo	Received

SAT-354	Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide - Results of a real world study	Mathias Jachs	Received

THU-354	Microarray analysis of virus-specific IgM and IgG antibodies significantly improves the serological diagnosis of Hepatitis E Virus infection	David Springer	Received

FRI-355	High frequency of hepatitis C virus reinfection following antiviral treatment in the North East of England	Sumar Askar	Received

THU-355	Hepatitis delta virus reflex testing in patients with Hepatitis B improves the HDV screening cascade: 10 years of real-world experience from Avicenne University Hospital, France	Segolene Brichler	Received

SAT-355	HBV RNA levels are associated with virological response to treatment with pegylated interferon alpha in patients with chronic hepatitis D virus infection	Lisa Sandmann	Received

SAT-356	Management of chronic hepatitis B virus infection within a large integrated health care setting: treatment patterns among kaiser permanente members in southern california, 2008 - 2019	Deborah Malden	Received

THU-356	T cell epitope mapping of hepatitis B virus in chronic infection	Marie Viuff	Received

SAT-357	Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody	Kosh Agarwal	Received

FRI-357	Direct acting antiviral agents improve survival in patients with hepatitis C virus related hepatocellular carcinoma	Hyun Young Woo	Received

THU-357	The Comparison of Tenofovir Alafenamide Fumarate with Tenofovir Disoproxil Fumarate in Preventing Hepatitis B Transmission in Mothers with High Viral Load: A Retrospective Cohort Study	Yunxia Zhu	Received

THU-358	Detection of notable hepatitis B virus serologic activity after hepatitis B surface antigen seroclearance	Danny Wong	Received

SAT-358	Quantification of HBV hepatocyte burden using novel multiplex immunofluorescence staining and image analysis reveals substantial reduction in HBV liver burden with anti-viral treatment	Abhishek Aggarwal	Received

FRI-358	Lack of Alpha-fetoprotein reduction after successful Hepatitis C treatment in patients with cirrhosis predicts the development of hepatocellular carcinoma during surveillance - a single unit real-world experience	Aoife Alvain	Received

THU-359	Comparison of on-treatment ALT or FIB-4 as an on-treatment biomarker of hepatitis B treatment for liver cirrhosis patients	JOO HYUN OH	Received

SAT-359	GST-HG141 inhibits de novo HBV cccDNA formation in cultured primary human hepatocytes	Vadim Bichko	Received

FRI-360	The long-term effect of Hepatitis C eradication by direct-acting antivirals on patients mood and quality of life as determined by the Becks Depression Inventory and EQ5D Quality of Life questionnaires - a single unit study	Aoife Alvain	Received

SAT-360	Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide	Victor de Lédinghen	Received

THU-360	Liver fibrosis burden determines risk of hepatocellular carcinoma among patients with hepatitis B surface antigen seroclearance	Lung-Yi Mak	Received

FRI-361	Assessing sustained virological response and reinfection from dried blood spots within an on-site hepatitis C diagnosis and treatment model of care in a harm reduction centre	Sabela Lens	Received

SAT-361	Impact of baseline viral load on hepatocellular carcinoma risk during antiviral treatment in non-cirrhotic patients with HBeAg-positive chronic hepatitis B	Won-Mook Choi	Received

THU-361	Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States	Robert Wong	Received

SAT-362	Therapeutic vaccination with CLB-3000 in a mouse model of chronic hepatitis B induces anti-HBs responses associated with functional cure	Aileen Rubio	Received

THU-362	Secular trend of the accuracy of hepatocellular carcinoma risk scores in treated chronic hepatitis B patients in 2005-2020: a territory-wide study of 48,706 subjects	Terry Cheuk-Fung Yip	Received

SAT-363	Evaluation of the disposition and mass balance recovery of vebicorvir, a first generation hepatitis B core inhibitor, in rats and humans	Rob Coover	Received

FRI-363	Lack of fibrosis remodelling in chronic hepatitis C post SVR, as demostrated by YKL-40, is predictive of hepatocellular carcinoma ocurrence	Maria Fernanda Guerra Veloz	Received

THU-363	Risk prediction of hepatocellular carcinoma in chronic hepatitis B patients outside current treatment criteria	Gi-Ae Kim	Received

FRI-364	HCV reinfection associated with IDU and cocaine use in a cohort of people with OUD: 4 Year follow-up data from the ANCHOR cohort	Elana Rosenthal	Received

SAT-364	Effect of tenofovir disoproxil fumarate treatment on intrahepatic viral burden and liver immune microenvironment in chronic hepatitis B patients with minimally elevated serum alanine aminotransferase	Abhishek Aggarwal	Received

THU-364	Suboptimal glycemic control is associated with adverse clinical outcomes in patients with chronic hepatitis B and diabetes mellitus	Lung-Yi Mak	Received

FRI-365	Noninvasive prediction of hepatocellular carcinoma development after oral antiviral therapy in patients with chronic hepatitis C: a multicenter study	Yu Rim Lee	Received

SAT-365	Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B	Benedetta Massetto	Received

THU-365	Statin use and surface antigen loss in patients with chronic hepatitis B	Shahed Iqbal	Received

THU-366	Patient engagement in hepatitis B clinical trials: HBV cure is a motivation for participation in all ethnically diverse patients	Almuthana Mohamed	Received

SAT-366	Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment nave patients with HBeAg positive chronic hepatitis B	Gregory Suess	Received

SAT-367	Safety, tolerability, pharmacokinetics, and preliminary antiviral activity of the capsid assembly modulator (CAM) ZM-H1505R after multiple escalatiing oral dosed in patients with chronic hepatitis B virus (CHB) Infection	Jiajia Mai	Received

THU-367	Anti-HDV reflex testing increases the number of hepatitis D cases diagnosed in both academic and community centers	Adriana Palom	Received

FRI-367	Direct-acting antiviral treatment in Albanian patients with chronic hepatitis C and advanced liver fibrosis	Liri Cuko	Received

THU-368	HBVoice: a framework to enhance advocacy for patients and communities affected by hepatitis B virus infection	Philippa Matthews	Received

FRI-368	Improved recurrence-free survival rates in patients with HCV-related hepatocellular carcinoma and sustained virological response to direct-acting antivirals	Anca Trifan	Received

SAT-368	Evaluation of renal and bone safety at 4 years in post-liver transplant patients with chronic kidney disease receiving Tenofovir Alafenamide for HBV prophylaxis	Edward Gane	Received

FRI-369	Long-term outcomes associated with task-shifting of HCV treatment by non-specialist providers: five year follow-up from the ASCEND cohort	Sarah Kattakuzhy	Received

THU-369	HBeAg-positive patients with HBsAg135IU/mL or HBcrAg3.6logU/mL have more chance to be HBsAg loss after nucleos(t)ide analogue cessation	Yandi Xie	Received

SAT-369	Functional cure based on pegylated interferon alpha therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China) - 3.5 years data update	Chan Xie	Received

THU-370	Serum markers of cccDNA transcriptional activity (HBcrAg and pre-genomic HBV RNA) and large HBsAg (LHBs) protein are predicting response to pegylated interferon in HDV infection	Ivana Carey	Received

SAT-370	Understanding the dynamics of HBsAg decline through model-informed drug development (MIDD) of JNJ-3989 and JNJ-6379 for the treatment of chronic hepatitis B virus infection (CHB)	Huybrecht Tjollyn	Received

FRI-371	Distinct hepatocellular carcinoma risks in treated chronic hepatitis C patients with different definitions of advanced chronic liver disease	Yen-Chun Liu	Received

SAT-371	Serum HBsAg and ddPCR HBV-DNA as predictive parameters of HBsAg loss after nucleo(s)tide analogue (NA) treatment discontinuation in non-cirrhotic patients with chronic hepatitis B	Anna Francesca Guerra	Received

THU-371	A decision-making model for prediction of a stable disease course in chronic hepatitis B patients	Imri Ofri	Received

SAT-372	Exploring hepatitis B virus as an immunotherapeutic target for clinical trials of adoptively transferred T cells	Spyridoula Vasileiou	Received

FRI-372	Hepatocellular carcinoma risks of liver fibrosis changes after viral eradication in chronic hepatitis C patients	Yen-Chun Liu	Received

THU-372	Healthcare resource utilization and costs of hepatitis delta in the United States: an analysis of all-payer claims database	Ankita Kaushik	Received

FRI-373	Change in fibrosis and clinical progression three years after sustained virological response induced by direct antiviral agents in HIV/HCV subjects	Maria Carnevali Frias	Received

SAT-373	Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings	Victor de Lédinghen	Received

THU-373	Validation of an internal hepatitis D virus DNA quantitative assay: developing assay suitable for global clinical application and clinical trials assessment	Natalie Bolton	Received

THU-374	Early increase in HBcrAg levels after peginterferon withdrawal predicts subsequent ALT flares	Sylvia Brakenhoff	Received

FRI-374	FOCUS Project: preliminary results toward hepatitis C Virus screening and elimination in Almería, Spain	Marta Casado	Received

SAT-374	Two-year safety and efficacy of tenofovir alafenamide in chronic hepatitis B: a HEllenic multicenter ReAl-life CLInical Study (HERACLIS-TAF)	George Papatheodoridis	Received

SAT-375	Treatment of chronic hepatitis B in sub-saharan Africa: 5-year results of a pilot program in Ethiopia	Asgeir Johannessen	Received

THU-375	Hepatitis B pre-genomic RNA differentiates HBeAg-negative disease from infection: time to refine disease stages with new biomarkers?	Bo Wang	Received

THU-376	Evaluating hepatitis delta virus disease prevalence and patient characteristics among adults in the United States: an analysis of all-payer claims database	Ankita Kaushik	Received

SAT-376	Decrease in the burden of integrated hepatitis B virus DNA in chronic hepatitis B patients with minimally elevated alanine aminotransferase on tenofovir disoproxil fumarate as revealed by long-read DNA-sequencing	David Pan	Received

FRI-376	Usefulness of longitudinal assessment of AFP in DAA cured HCV cirrhotic patients to predict the developmente of HCC	Eleonora Alimenti	Received

SAT-377	Serum HBV RNA levels are associated with risk of hepatitis flare after stopping NA therapy in HBeAg-negative patients	Alexander Thompson	Received

FRI-377	A 4 Year Multi-Centre Study of Persons Who Inject Drugs in Luxembourg, looking at Hepatitis C Virus Seroprevalence, Treatment Uptake and Reinfection Rates	Madiha Sharaf	Received

THU-377	Hepatitis delta in Northern Portugal - a long-term follow-up study	Isabel Garrido	Received

SAT-378	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive patients with chronic hepatitis B	Jihye Lim	Received

THU-378	Impact of hepatitis B virus infection on liver-related death among people tested for HBV in British Columbia: results from a large longitudinal population-based cohort study	Makuza Jean Damascene	Received

SAT-379	Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study	Alessandro Loglio	Received

SAT-380	The orally available sodium/taurocholate co-transporting polypeptide inhibitor A2342 blocks hepatitus B and D entry in vitro	Paris Fossa	Received

THU-380	Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the setting of HBeAg positive infection	Romina Salpini	Received

THU-381	In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy	Stefano DAnna	Received

FRI-381	Benefits associated with HCV cure in people with mental disorders	Elias Benabadji	Received

SAT-381	Comparative performance analysis between manual and automatic RNA extraction to quantify HDV RNA by RoboGene 2.0 kit in untreated and bulevirtide-treated HDV patients	Sara Colonia Uceda Renteria	Received

FRI-382	Dismal prognosis for cirrhotic HCV patients after initial DAA treatment failure, rescue therapy may be life-saving	Johan Westin	Received

THU-382	Absence of hepatitis B virus (HBV) in at-risk infants receiving early antiretroviral therapy in a cohort of HIV-transmitting mothers in KwaZulu-Natal, South Africa	Anna McNaughton	Received

SAT-383	ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents covalently closed circular DNA formation by disruption of incoming capsids	Gregory Suess	Received

THU-383	Rising clinical and economic burden among hepatitis D patients who attended Spanish hospitals	Maria Buti	Received

FRI-383	Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool	David Burger	Received

THU-384	Analysis from national hospital discharge records database in Spain : increased baseline comorbidity burden including liver severity among HDV coinfection versus HBV monoinfection patients	Maria Buti	Received

FRI-384	Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset	Olivia Burgess	Received

SAT-384	Real-word high adherence to hepatitis B antiviral treatment practice guidelines in Israel	Yana Davidov	Received

SAT-385	No detectable resistance to bulevirtide in participants with chronic hepatitis D (CHD) through 24 weeks of treatment	Julius Hollnberger	Received

THU-385	Value of intrahepatic HBV markers in virologically suppressed HBV and HDV infected patients	Ester García-Pras	Received

FRI-385	Sofosbuvir plus velpatisvir for 8 weeks in patients with acute hepatitis C: multicenter, single arm, phase 2 study (The HepNet acute HCV-V study)	Julia Kahlhfer	Received

THU-386	Hepatitis Delta virus infection in patients with chronic hepatitis B is associated with greater risk of liver disease progression and liver-related mortality: a systematic review and meta-analysis	Robert G. Gish	Received

FRI-386	Full-length genome characterization of inherently resistant african HCV genotype 1, subtype 1l in patients failing DAA-based therapy	Erwan Vo Quang	Received

SAT-386	The HBV siRNA, ALG-125755, demonstrates a favourable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model	Megan Fitzgerald	Received

SAT-387	Hepatitis delta management in the United Status: an analysis of all-payer claims database	Ankita Kaushik	Received

FRI-387	Treating HCV in dual diagnosis acute psychiatric inpatients with substance use disorder	vera dreizin	Received

THU-387	The serum markers of cccDNA transcriptional activity have a role in predicting long-term outcomes in children with perinatally acquired HBV infection	Christiana Moigboi	Received

FRI-388	Eight-weeks of glecaprevir/pibrentasvir is well tolerated and yields high sustained virological response in HCV-infected treatment-naive patients with compensated cirrhosis: the CREST study	Laura Whiteley	Received

SAT-388	Evaluation of the drug-drug interaction profile of vebicorvir, a first-generation hepatitis B core inhibitor: findings from phase 1 and phase 2a studies	Gregory Suess	Received

THU-388	Presence of liver inflammation and fibrosis in Asian patients with chronic hepatitis B in the grey zone	Jiacheng Liu	Received

THU-389	Characteristics and renal function in patients with chronic hepatitis B virus infection: baseline data from the phase 2b B-Clear study	Seng-Gee Lim	Received

SAT-389	Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities	Gregory Suess	Received

FRI-389	HCV-RNA viral load fingerstick assay as a simplified strategy for screening and linkage to care of people who use drugs attending 3 french addiction centers	Denis Ouzan	Received

SAT-390	EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in nuc-suppressed chronic hepatitis B patients	Jordan Feld	Received

THU-390	Characterisation of baseline complement values in patients with chronic hepatitis B virus infection in the phase IIb B-clear study	Jennifer Cremer	Received

FRI-390	Pangenotypic and genotype-specific antivirals in the treatment of genotype 4 infected patients with HIV coinfection	Dorota Zarebska-Michaluk	Received

THU-391	Estimations of the global prevalence and clinical burden of occult hepatitis B infection (OBI): a systematic review and meta-analysis	Yu Ri Im	Received

SAT-391	Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients	Emily P. Thi	Received

FRI-391	Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure	Julia Dietz	Received

THU-392	Time for universal screening for hepatitis D? A study describing screening patterns, characteristics and outcomes of hepatitis D virus infection	Rohit Nathani	Received

SAT-392	Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB)	Edward Gane	Received

FRI-392	Real-life effectiveness and safety of sofosbuvir/velpatasvir in difficult to treat hepatitis C patients	Hyun Young Woo	Received

THU-393	Distribution of patients by guideline-defined disease phase and/or grey zones in B-Clear, an international multicentre clinical trial	Seng-Gee Lim	Received

SAT-393	EDP-514, a potent pangenotypic class II hepatitis B virus core inhibitor, demonstrates significant HBV DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B patients	Man-Fung Yuen	Received

FRI-393	Polypharmacy and prevalence of multi drug-drug interactions in hepatitis C patients treated with pangenotypic direct acting antivirals: an analysis from three european countries	Alessandra Mangia	Received

THU-394	Benign course of HBV reactivations during DAAs in untreated ENI with HBV-HCV co-infections correlates with different HBsAg kinetics compared to NAs treated CHB patients	Piero Colombatto	Received

FRI-394	Use of comedication in patients with hepatitis C and addiction or drug abuse treated with direc-acting antivirals: implication in drug-drug interactions	Marinela Mendez	Received

SAT-394	Increased HBsAg reduction and relapse outcomes in HBeAg negative patients with chronic hepatitis B after nucleos(t)ide analogue withdrawal: 4.5 year follow up of the Toronto STOP Study	Arif Sarowar	Received

FRI-395	Five years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-October 2021	Tengiz Tsertsvadze	Received

SAT-395	Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver	Emily P. Thi	Received

THU-395	Predictors of advanced liver fibrosis in chronic hepatitis B patients in the daily clinical practice	Fadi Abu Baker	Received

THU-396	Metabolic associated fatty liver disease is associated with appendicular lean soft tissue abnormalities in patients with chronic hepatitis B	Luciana Diniz Silva	Received

SAT-396	Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA chronic hepatitis B patients	Sharie C Ganchua	Received

FRI-396	Simplifying mathematical-based response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients	Harel Dahari	Received

THU-397	The course of COVID-19 infection in patients with chronic hepatitis B and Delta	onur keskin	Received

FRI-397	Epidemiology of hepatitis B virus infection among hepatitis C (HCV) infected patients treated within HCV elimination program in Georgia	Senad Handanagic	Received

SAT-397	Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells	Emily P. Thi	Received

THU-398	Serum soluble program cell death-1 is predictive of hepatocellular carcinoma in untreated chronic hepatitis B patients	Rachel Wen-Juei Jeng	Received

SAT-398	Characterizing of hepatitis B virus serum RNA kinetics during TDF plus pegylated interferon alfa-2a with and without nucleic acid polymers	Harel Dahari	Received

FRI-398	Direct-acting antivirals and the risk of hepatitis B reactivation in hepatitis B and C coinfected patients: a systematic review and meta-analysis	JOO HYUN OH	Received

FRI-399	Inhibition of high fitness viruses by different antiviral strategies when the infection has started	Carlos García-Crespo	Received

THU-399	Parameters related to ALT elevation in patients with HBeAg negative chronic infection	Fulya Gunsar	Received

SAT-399	Early antiviral efficacy of tenofovir alafenamide fumarate in the initial treatment of chronic hepatitis B patients with normal ALT	Xin Chi	Received

FRI-400	Treatment of hepatitis C in primary healthcare in the country of Georgia	Tengiz Tsertsvadze	Received

THU-400	Clinical evidence for unconventional hepatitis delta virus infections in endemic countries	Mary Rodgers	Received

SAT-400	Viral and ALT kinetics after nucleos(t)ide analogue withdrawal among patients who remain off-therapy: results from a global, multi-ethnic cohort of chronic hepatitis B patients (RETRACT-B study)	Grishma Hirode	Received

SAT-401	Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B	Francois Gonzalvez	Received

THU-401	Rapid point-of-care test for hepatitis B core-related antigen (HBcrAg) to identify HBV-infected patients eligible for antiviral therapy	Yusuke Shimakawa	Received

FRI-401	Optimal screening and linkage to care model to achieve hepatitis C elimination targets in Georgia	Tengiz Tsertsvadze	Received

SAT-402	Incorporation of novel ASO chemistries significantly improves the potency and durability of HBV ASOs in the AAV-HBV mouse model	Jin Hong	Received

FRI-402	Establishing a protocol for management and DAA treatment of HCV during pregnancy: adherence to a co-located care protocol	Tatyana Kushner	Received

THU-402	Prevalence of HBV infection and receiving antiviral treatment for eligible patients in blood relatives from clustering families of HBV infection with unfavorable prognoses and cascading of care linked to treatment in West China	yuan yang	Received

THU-403	Liver inflammation in asian chronic hepatitis B patients with detectable HBV-DNA and normal alanine aminotransferase according to diverse upper limits of normal	Rui Huang	Received

FRI-403	Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial	Brian Conway	Received

FRI-404	High efficacy and safety of pan-genotypic direct-acting antiviral regimens in adolescents and children: a global systematic review to inform new World Health Organization recommendations	Giuseppe Indolfi	Received

THU-404	Diversity of circulating HBV genomes and impact on viral infection	Jules Sotty	Received

FRI-405	Early vs. late treatment for hepatitis C virus discordant solid organ transplantation and direct acting antivirals: a meta-analysis	Madison Gunn	Received

THU-405	Chronic hepatitis delta with normal ALT and hepatitis D viremia	Cihan Yurdaydin	Received

SAT-405	Evaluation of quantitative HBsAg levels in chronic hepatitis B - a targeted literature review	Vera Gielen	Received

FRI-406	Effectiveness of pangenotypic retreatment of HCV infection after prior failure of pangenotypic therapies	Robert Flisiak	Received

SAT-406	Nucleoside/nucleotide analogoues monotherapy is safe and efficient for the prevention of HBV flare-ups after liver transplantion in the long term	orly sneh arbib	Received

THU-406	Hepatitis B core related antigen, not as good as it seems: a critique and systematic review	Yong Chuan Tan	Received

THU-407	Utilizing phenotyping algorithms as tools for increasing linkage to guideline-concordant care in patients at risk for hepatitis B	Brooke Wyatt	Received

FRI-407	Infrequent Hepatitis C genotypes/subtypes in patients treated with DAA-based regimens: successes and failures	Isaac Ruiz	Received

SAT-407	A new method to identify co-variation in hepatitis B virus whole genome sequences identifies networks of polymorphisms associated with drug resistance	Philippa Matthews	Received

SAT-408	Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline	Katja Deterding	Received

FRI-408	Preemptive treatment with glecaprevir and pibrentasvir prevents HCV transmission from HCV viraemic donors to solid organ transplant recipients (single centre experience)	So&328;a Fra&328;ková	Received

THU-408	Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients	Jinlin HOU	Received

FRI-409	Hepatitis C care cascade challenges in the homeless population. A case by case model of delivering care	Maria Fernanda Guerra Veloz	Received

SAT-409	Low levels of qHBsAg and tenofovir therapy are associated with successful treatment withdrawal in HBeAg negative chronic hepatitis B: results from spanish multicentric study	Anna Pocurull	Received

THU-409	Presence of HbeAg, HBV DNA in cord blood and down regulation of TLR9 may act as predictive marker for HBV Mother to child transmission	Simanta Kalita	Received

SAT-410	Preliminary results of the effectiveness and safety of Tenofovir Alefenamide Fumarate prophylaxis in HBV-infected individuals, who received chemo/immunosuppressive therapy	FEYZA GUNDUZ	Received

THU-410	Patients with CHD coinfection have greater comorbidities, higher healthcare resource use and costs than CHB monoinfection - results from a Spanish national hospital database	Maria Buti	Received

FRI-410	Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment nave patients with compensated cirrhosis: real-world experience from Taiwan HCV Registry	Chao-Hung Hung	Received

THU-411	Clinical features predictive of cirrhosis in a large cohort of patients with chronic hepatitis delta infection- Insights from the D-LIVR trial	Ohad Etzion	Received

FRI-411	Reported safety of HCV direct-acting antivirals with opioids: 2017 to 2021	Anthony Martinez	Received

SAT-411	Real life efficacy, renal and lipid profile data of tenofovir alafenamide in switched chronic hepatitis B patients	Omer Fehmi Tabak	Received

THU-412	Establishment of a new diagnostic model for significant liver tissue damage in patients with chronic hepatitis B virus infection in the immune tolerance phase	Airong Hu	Received

SAT-412	Mathematical modeling of HDV RNA kinetics suggests high peginterferon Lambda efficacy in blocking viral production: insights from the LIMT-1 study	Harel Dahari	Received

SAT-413	Heterologous prime-boost immunotherapy circumvents tolerance and induces broadly neutralizing antibodies that protects against hepatitis B and D co-infection and hepatitis D super-infection	Lars Frelin	Received

THU-413	Provider factors shaping Hepatitis Delta Screening	Dewan Giri	Received

FRI-414	Impact of the presence of the infectious disease specialist in Addiction Services (SerDs) as a Point-of-Care to meet WHO goal of HCV eradication	Chiara Fanelli	Received

SAT-414	Real-world data on treatment with bulevirtide in patients with chronic hepatitis B and D coinfection	Toni Herta	Received

THU-414	Changes of enhanced liver fibrosis score predict hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral treatment	Yan Liang	Received

FRI-415	Eliminating hepatitis C virus infection in prisons: 7 years of experience	Frederico Miguel Duarte	Received

SAT-415	Higher rates of virological relapse after nucleos(t)ide analogue withdrawal in HBeAg-negative versus positive chronic hepatitis B patients: results from a global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B Study)	Grishma Hirode	Received

THU-415	Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study	Syed Hassan Bin Usman Shah	Received

FRI-416	Real-World Value and Innovation of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C at Kaiser Permanente Southern California	Alon Yehoshua	Received

THU-416	Point of care screening tests for hepatitis B and commitment of a dedicated nurse lead to succesful linkage to care of ethnic minorities	Axelle Vanderlinden	Received

SAT-416	Real life efficacy and tolerability of Tenofovir alafenamde fumarate in liver transplant recipients: a multicenter study	Suna Yapali	Received

SAT-417	Impact of patient-related factors on the pharmacokinetics of Bulevirtide	Renu Singh	Received

THU-417	Prediction of comprehensive prognosis through computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B	Heejin Cho	Received

THU-418	Analysis on the normal threshold of alanine aminotransferase level based on liver pathology in patients with chronic hepatitis B	Airong Hu	Received

FRI-418	Treatment options for hepatitis C in pregnancy: A systematic review of the evidence and future research needs	Lindsey Hiebert	Received

SAT-418	Reduction of liver stiffness in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study	Heejin Cho	Received

SAT-419	Toll-like receptor 8 agonism activates monocytes and induces antiviral cytokine production by T-cells in HIV and chronic hepatitis B coinfection	Lydia Tang	Received

THU-419	Prevalence rates and eligibility for antiviral treatment against hepatitis B in Casamance, Senegal	Vic Arendt	Received

THU-420	Comorbidities, and not viral load, are predictors of cirrhosis in AgHBe-negative chronic infection	Sara Archer	Received

SAT-420	Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switching to tenofovir alafenamide - an interim analysis	Pin-Nan Cheng	Received

SAT-421	Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis	Suna Yapali	Received

THU-421	A systematic literature review and meta-analysis of primary sources reporting health state preference values in chronic hepatitis B, C, and D	Sarah Hofmann	Received

SAT-422	Effects of the siRNA JNJ-3989 and/or the capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): Results from the REEF-1 study	Man Fung Yuen	Received

THU-422	Hepatitis B transmission in early life in very remote Aboriginal communities in northern Australia	Jane Davies	Received

THU-423	the changing scenario of HBV chronic related disease in the transplant setting	sara battistella	Received

SAT-423	Safety, pharmacokinetics and antiviral activity of GST-HG141, a hepatitis B virus capsid assembly modulator, in subjects with chronic hepatitis B	Vadim Bichko	Received

SAT-425	Randomized, double-blind, placebo-controlled trial of Tenofovir Alafenamide in children and adolescents with Chronic Hepatitis B	Kathleen Schwarz	Received

SAT-426	The discovery of AMS-I-1274, a high potent and orally active capsid-assembly modulator against hepatitis B virus	Jung-Hee Kim	Received

SAT-427	Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and naive chronic hepatitis B patients: 48-week treatment and post-treatment follow up	Man-Fung Yuen	Received

SAT-428	Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB on nucleos(t)ide analogues	Eleanor Barnes	Received

SAT-429	Bulevirtide monotherapy for 48 weeks in HDV patients with compensated cirrhosis and clinically significant portal hypertension	Elisabetta Degasperi	Received

SAT-430	Bulevirtide avoids future clinical events and related costs compared to pegylated-interferon alpha in chronic hepatitis D in Spain	Raquel Domínguez-Hernández	Received

THU-431	Outcomes of pregnancy in patients with autoimmune hepatitis in the Netherlands	Susan Fischer	Received

SAT-431	Quantitative HBsAg(qHBsAg) as an endpoint to stop nucleos(t)ide analogues in Chronic Hepatitis B: A meta-analysis with meta-regression	Seng Gee Lim	Received

THU-432	Cholangiopathy after severe COVID-19: what do we know so far?	Valéria Ferreira de Almeida e Borges	Received

SAT-432	Low level of HBcrAg is beneficial to functional cure obtained with pegylated interferon therapy in inactive HBsAg carriers	Zhenhuan Cao	Received

SAT-433	Comparative risk of hepatocellular carcinoma in patients with chronic hepatitis B receiving tenofovir- or entecavir-based regimens: a meta-analysis using individual patient data	Isabel Haber	Received

THU-433	Enhanced liver fibrosis score correlates with transient elastography in patients with treated autoimmune hepatitis	Anna Stoelinga	Received

SAT-434	VIR-2218 plus VIR-3434 combination therapy reduces hepatitis B virus surface antigen levels in vivo	Julia Noack	Received

THU-434	Rationale for evaluation of PLN-74809 treatment in participants with primary sclerosing cholangitis in Phase 2a study INTEGRIS-PSC	Éric Lefebvre	Received

THU-435	Acute hepatitis after COVID-19 vaccine: case series by the International autoimmune hepatitis group (IAIHG) and the european reference network on hepatological diseases (ERN RARE-LIVER)	Benedetta Terziroli Beretta-Piccoli	Received

SAT-435	Safety, pharmacokinetics, and antiviral activity of the S-antigen Transport Inhibiting Oligonucleotide Polymers (STOPS) drug candidate ALG-010133 in subjects with chronic hepatitis B	Edward J Gane	Received

THU-436	Scheduled endoscopic program for patients with primary sclerosing cholangitis improves transplant-free survival and enables early risk stratification	Burcin zdirik	Received

SAT-436	Costimulation of CD40 and type-I interferon immune pathways by a bifunctional molecule in HBV infection models and healthy non-human primates	Xavier Marniquet	Received

SAT-437	IMC-I109V, a novel T cell receptor (TCR) bispecific (ENVxCD3) designed to eliminate HBV-infected hepatocytes in chronic HBV patients: initial data from a first-in-human study	Lucy Dorrell	Received

THU-437	Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study	Kristin Kaasen Jrgensen	Received

SAT-438	Long-term outcomes after cessation of antiviral therapy in HBeAg negative patients	Rachel Wen-Juei Jeng	Received

THU-438	Analyses of obeticholic acid treatment retention in UK patients based on medicine delivery data	Carl Gibbons	Received

THU-439	Real-world prevalence of pruritus with obeticholic acid: a systematic literature review and meta-analysis	Leighland Feinman	Received

SAT-439	Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study	Shihyun You	Received

SAT-440	Most patients with advanced cirrhosis treated with bulevirtide monotherapy have a non-monophasic HDV RNA decline patterns: an interim kinetic analysis of real-life setting	Harel Dahari	Received

THU-440	Cognitive symptoms in non-cirrhotic primary biliary cholangitis	Naw April Phaw	Received

SAT-441	Mechanistic Pharmacokinetics/Pharmacodynamics modelling of the simultaneous effects of bepirovirsen on Hepatitis B surface antigen and alanine transaminase changes in Chronic Hepatitis B patients: Phase 2b analysis to inform Phase 3 decision-making	Ahmed Nader	Received

THU-441	Screening and surveillance of biliary neoplasia based on brush cytology in primary sclerosing cholangitis (PSC): prevalence and outcomes	Martti Frkkil	Received

THU-442	Impact of pruritus in primary sclerosing cholangitis (PSC): a multinational survey	Kris Kowdley	Received

SAT-442	Improved treatment response and bone density in patients with chronic hepatitis B (CHB) switched to tenofovir alafenamide (TAF) from other nucleos(t)ide analogue: 96-week results from a prospective multinational study	Eiichi Ogawa	Received

SAT-443	Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg subjects	Timothy Eley	Received

THU-443	A dynamic approach to modelling baseline disease status and ALT elevation over follow-up on clinical-event free survival in autoimmune hepatitis: a canadian multicentre cohort	Christina Plagiannakos	Received

SAT-444	Identification of novel antivirals against Hepatitis Delta Virus infection via High Throughput Screening	Eirini Tseligka	Received

THU-444	Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study	Marcus Maximilian Mcke	Received

SAT-445	Generation and functional analsis of spacer modified HBV-specific chimeric antigen receptors that harbor a Fab fragment as binding domain	Zhe Xie	Received

THU-445	The efficacy of combined treatment of bezafibrate and ursodeoxycholic acid was reduced in patients with primari cholangitis at advanced stage	Kosuke Matsumoto	Received

THU-446	Extrahepatic autoimmune diseases in autoimmune hepatitis: effect on mortality	Rasmine Birn-Rydder	Received

SAT-446	Randomised double-blind study of nitazoxanide for virologically suppressed HBeAg negative Chronic Hepatitis B	Yong Chuan Tan	Received

SAT-447	Low-level viremia in patients with chronic hepatitis B receiving entecavir, tenofovir and tenofovir alafenamide	xiaohao Wang	Received

THU-447	Confidence in treatment is contributing to quality of life in patients with autoimmune liver diseases. The results of ERN-RARE Liver online survey	Ewa Wunsch	Received

SAT-448	Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729	Man-Fung Yuen	Received

THU-448	A pilot study of PBC symptom management with melatonin and fenofibrate: the PIMBLE study	Amanda Nicoll	Received

THU-449	Portal hypertension-associated clinical features in patients with primary biliary cholangitis are of distinct prognostic value	Lukas Burghart	Received

SAT-449	Tenofovir alafenamide fumarate increased lipid levels in hepatitis B virus patients	Wenjuan Zhao	Received

SAT-450	Off-therapy cure of Hepatitis Delta after 3 years of Bulevirtide monotherapy in a patient with compensated advanced cirrhosis	Maria Paola Anolli	Received

THU-450	The low incidence of HBV reactivation among anti-HBc subjects on immunotherapy reduces the impact of suboptimal screening rate	Laia Aceituno	Received

THU-451	The ABCB4 variant c.711 increases liver injury in PBC but not in PSC: prospective analysis with a median follow-up of 7 years in 331 patients	Marcin Krawczyk	Received

SAT-451	Combination treatment of a PAPD5/7 inhibitor with an antisense oligonucleotide bepirovirsen with concurrent dosing shows additive HBsAg decreases in the AAV-HBV mouse model	Martin Leivers	Received

FRI-451	Over-responsiveness of the IL-6/STAT3 pathway in inflammatory CD4 T cells of patients with primary sclerosing cholangitis	Leona Dold	Received

SAT-452	Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection not on stable nucleos(t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study	Seng Gee Lim	Received

FRI-452	Dosing ileal bile acid transporter inhibitors in the fasted state minimizes gastrointestinal adverse effects while maintaining pharmacodynamic effect	Cory Kostrub	Received

THU-452	A multicentric study to estimate mortality and graft loss risk after liver transplantation (LT) in patients with recurrent primary biliary cholangitis (PBC)	Aldo Montano-Loza	Received

SAT-453	Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos(t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study	Man-Fung Yuen	Received

THU-453	Associations between novel serum biomarkers chitinase-2-like protein (YKL-40), type IV collagen, and thrombospondin-2 (TSP-2) with fibrosis stage and clinical outcomes in patients with primary sclerosing cholangitis (PSC)	Jun Xu	Received

THU-454	MRCPTM - derived biliary metrics are associated with disease severity and clinical outcomes in patients with primary sclerosing cholangitis	Nora Cazzagon	Received

FRI-454	Association of bile acids composition and synthetic pathway with therapeutic effect of bezafibrate in chronic cholestatic liver disease	Manami Iida	Received

THU-455	Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)	Jun Xu	Received

FRI-455	Reduced hepatic expression of PPAR alpha in primary biliary cirrhosis is modulated by miR-155	Monika Adamowicz	Received

FRI-456	cholangiocytes-specific deletion of sphingosine-1-phospholipid receptor 1 attenuate cholestasis induced liver injury and fibrosis	zihang yuan	Received

THU-456	Association between patient-reported outcome measures and surrogate markers of liver fibrosis in large-duct primary sclerosing cholangitis	Emmanuel Selvaraj	Received

THU-457	Association between patient-reported outcome measures and severity of cholangiopathy in large-duct primary sclerosing cholangitis	Emmanuel Selvaraj	Received

FRI-457	Pruriceptor activating compounds in the eneterohepatic cycle in cholestatic itch	Frank Wolters	Received

FRI-458	Characterising the early inflammatory landscape of primary sclerosing cholangitis	Calli Dendrou	Received

THU-458	Ultrasound for the diagnosis of gallbladder polyps in PSC: polyps greater than 8 mm indicate malignancy	Johannes Altenmller	Received

THU-459	Temporal changes in patient-reported outcome measures stratified by liver fibrosis severity in large-duct primary sclerosing cholangitis	Emmanuel Selvaraj	Received

THU-460	Temporal increase in interquartile range iron-corrected T1 in high-risk patients with large-duct primary sclerosing cholangitis	Emmanuel Selvaraj	Received

FRI-460	Copper accumulation in chronic cholestatic disease augments liver damage by impairment of mitochondrial function	Dennis Koob	Received

THU-461	Seladelpar treatment of patients with primary biliary cholangitis (PBC) for 2 years improves the GLOBE PBC score and predicts improved transplant-free survival	Yun-Jung Choi	Received

FRI-461	The IgG4-related cholangitis autoantigen laminin 511-E8 stabilizes the biliary bicarbonate umbrella in human cholangiocytes	David Trampert	Received

FRI-462	The risk-variant rs56258221 at the BACH2-locus associates with skewed polarization of naive CD4 T cells towards pro-inflammatory phenotypes in primary sclerosing cholangitis	Jonas Bahn	Received

THU-462	Validation of a novel method of identifying patients with Primary Sclerosing Cholangitis (PSC) in a canadian population	Harshil Patel	Received

FRI-463	Single-cell profiling of liver B cells identifies distinct gene expression and reactivities of expanded B cell clonotypes in primary sclerosing cholangitis	Brian K. Chung	Received

THU-463	The prevalence of primary biliary cholangitis (PBC) is on the rise: a canadian population-based study	Bryce Tkachuk	Received

FRI-464	The rs429358 apolipoprotein E (APOE) polymorphism is associated with increased liver injury in patients with autoimmune hepatitis	Maciej K. Janik	Received

THU-464	Rituximab is a safe and effective treatment for patients with autoimmune hepatitis: results from the Spanish registry for cholestatic and autoimmune hepatitis	Mar Riveiro-Barciela	Received

FRI-465	Intrabiliary injection of MAIT antigens induces cholangitis in mice	Kathrine Sivertsen Nordhus	Received

THU-465	Autoimmune hepatitis diagnosed after COVID-19 vaccination. Results from the spanish registry for autoimmune and cholestatic hepatitis	Ana Barreira	Received

THU-466	A prospective trial of a gluten free diet in primary sclerosing cholangitis with associated colitis	Timur Liwinski	Received

FRI-466	TGF beta 2 fuels inflammation and fibrosis in cholestatic liver disease through macrophage and myofibroblast recruitment and activation	Jan Albin	Received

THU-467	The international autoimmune hepatitis group retrospective registry: quality assessment and analysis of clinical characteristics and liver-related outcome	Charlotte Slooter	Received

FRI-467	Liver-specific Tsg101 depletion causes apoptosis, cell death and liver failure	Surui Wang	Received

THU-468	Liver inflammation activity in autoimmune hepatitis patients with normal ALT and IgG levels	Jiacheng Liu	Received

FRI-468	B cell reactivation in autoimmune hepatitis after immunosuppression withdrawal	Elena Perpiñan	Received

FRI-469	Serum sterols indicate modified cholesterol homeostasis in cirrhotic patients with PBC and correlate with response to treatment with ursodeoxycholic acid	Wiktor Smyk	Received

THU-469	Novel screening test for primary sclerosing cholangitis: the role of serology, liver function tests, histology and radiology	Nina Barner-Rasmussen	Received

THU-470	More than just an itch: impact of cholestatic pruritus in primary biliary cholangitis (PBC) on health-related quality of life (HRQoL)	Helen Smith	Received

FRI-470	Preserved MAIT cell proinflammatory function in children with Autoimmune Liver Disease	Suz Warner	Received

THU-471	Isolated IgG elevation is not associated with worse outcome in patients with autoimmune hepatitis	ALVARO DIAZ GONZALEZ	Received

THU-472	Linerixibat doseresponse analysis of C4 concentrations as a quantitative approach to predict gastrointestinal tolerability	Fernando Carreño	Received

THU-473	Urinary sulfated progesterone metabolites are diagnostic markers for cholestatic pregnancy and markers of treatment response to ursodeoxycholic acid	Luiza Borges Manna	Received

THU-474	COVID-19 vaccine induced autoimmune hepatitis - a first case series from India	Sowmya Iyengar	Received

THU-475	Lymphoma in IgG4-related disease: should we be concerned?	Arif Hussenbux	Received

THU-476	Measurement properties of the PBC-10 in a dutch population	Maria van Hooff	Received

THU-477	Gluco-regulatory disturbances in primary biliary cholangitis and non-alcoholic fatty liver disease compared with healthy individuals	Anne-Sofie Houlberg Jensen	Received

THU-478	Proportion of time and degree to which liver biochemistries are out-of-range predicts time to first occurrence of negative hepatic outcomes in people with primary biliary cholangitis	TImothy Ritter	Received

THU-479	Outcomes following immune checkpoint inhibitor re-challenge in patients who developed grade 3 and 4 hepatotoxicity	Amy Hicks	Received

THU-480	Development of a novel MRCP-score for patients with primary sclerosing cholangitis, and assessment of agreement and prognostic value	ARISTEIDIS GRIGORIADIS	Received

THU-481	Right and left lobe biopsies by mini-laparoscopy reveals clinically significant sampling error in staging and grading in AIH	johannes hartl	Received

THU-482	Should we seek complete liver tests normalization in primary biliary cholangitis? Data from ColHai Registry	Maria Carlota Londoño	Received

THU-483	Home-based Exercise in patients with refractory fatigue associated Primary Biliary Cholangitis: Final results from the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) clinical trial	Alice Freer	Received

THU-484	Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database	Joe Konen	Received

THU-485	Investigation of linerixibat 40mg BID for cholestatic pruritus of primary biliary cholangitis (PBC); further data from the Phase 2b GLIMMER study to support the Phase 3 GLISTEN study	James Fettiplace	Received

FRI-485	TIPS insertion leads to partial reversal of systemic inflammation in patients with decompensated liver cirrhosis	Lena Stockhoff	Received

SAT-486	Evaluation of Interleukin-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis	Simon Johannes Gairing	Received

SAT-487	Evaluation of statins as a new therapy to alleviate chronotropic dysfunction in cirrhotic rats	Qamar Niaz	Received

THU-487	Post-COVID-19 CHOLANGIOPATHY: Does SARS-CoV-2 play a relevant role in HISTOPATHOLOGICAL findings?	Valéria Ferreira de Almeida e Borges	Received

FRI-487	Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)	Alessandra Mangia	Received

THU-488	Examining the role of thiopurine metabolite testing in the management of patients with autoimmune hepatitis	Andrew Roberts	Received

FRI-488	A simple model for predicting survival in cirrhotic patients undergoing portosystemic shunt embolization	Won-Mook Choi	Received

SAT-488	The effect of sarcopenia on survival of patients with cirrhosis: a systematic review and meta-analysis	Xinxing Tantai	Received

THU-489	Patient reported symptom burden in primary biliary cholangitis and how to inform trial design	Aaron Wetten	Received

FRI-489	Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: relation to severity?	Puria Nabilou	Received

SAT-489	Effectiveness of probiotics in the secondary prevention of hepatic encephalopathy among cirrhotic patients	Muhammad Farooq Hanif	Received

SAT-490	Sarcopenia as a predictor of mortality and complications in cirrhosis patients - A prospective cohort study	NIDHIN DEVADAS	Received

FRI-490	Gender affects the association between serum creatinine levels and clinical response to terlipressin in patients with hepatorenal syndrome type of acute kidney injury	Khurram Jamil	Received

THU-490	A randomized control trial evaluating the impact of a web-based mind-body wellness intervention for patients with primary biliary cholangitis	Makayla Watt	Received

FRI-491	A novel cirrhotic ascites severity score predicts one-year mortality better than the classification into refractory or diuretic-responsive ascites	Rasmus Hvidbjerg Gantzel	Received

SAT-491	Diagnosis and pathophysiological analysis of sarcopenia using liver MR in chronic liver disease	ATSUSHI NAKAMURA	Received

THU-491	Health-related quality of life in patients with primary sclerosing cholangitis: a longitudinal population-based cohort study	Bregje Mol	Received

FRI-492	A network meta-analysis of numbers needed to treat to prevent an episode of overt hepatic encephalopathy in patients with cirrhosis treated for at least 6 months with lactulose alone, or lactulose plus rifaximin-alpha	Eric Ngonga Kemadjou	Received

SAT-492	Use of a cirrhosis database can positively impact patient care in United Kingdom practice	Jessica Shearer	Received

FRI-493	Transjugular intrahepatic portosystemic shunt versus balloon-occluded transvenous obliteration for the management of ectopic varices	Ranya Selim	Received

THU-493	COVID-19 in patients with cirrhosis: insights from the multinational LEOSS registry	Jonathan Frederik Brozat	Received

SAT-493	Psychomotor speed from minimal hepatic encephalopathy testing is associated with physical frailty in patients with end-stage liver disease	Alexandra Steinberg	Received

FRI-494	Identification of potential new serum biomarkers for clinically significant portal hypertension by proteomic profiling of circulating extracellular vesicles	Frane Pastrovic	Received

SAT-494	A multistrain probiotic increases serum glutamine/glutamate ratio in patients with cirrhosis. A metabolomic analysis	German Soriano	Received

THU-494	Serum metabolites on admission associate with the development of nosocomial infections in inpatients with cirrhosis	Jasmohan S Bajaj	Received

THU-495	Association of impaired neutrophil migration with adverse outcomes in patients with liver cirrhosis	Mona-May Langer	Received

FRI-495	Factors influencing survival in cirrhotic patients with hepatic hydrothorax	Sarah Romero	Received

SAT-495	The composition of the bile acid pool is closely associated with fibrosis in the heart and liver of patients with cirrhosis	Signe Wiese	Received

FRI-496	Hepatic venous pressure gradient (HVPG) measured at events is lower in non-alcoholic fatty liver disease (NAFLD) associated cirrhosis as compared to alcoholic cirrhosis	Svetlana Adamcova Selcanova	Received

THU-496	Renal and circulatory effects of terlipressin in patients with hepatorenal syndrome assessed by magnetic resonance imaging	Puria Nabilou	Received

SAT-496	SBP vs. non-SBP bacterial infections at admission have comparable outcomes in a multi-center cohort of inpatients with cirrhosis	Jacqueline OLeary	Received

FRI-497	Low subcutaneous adipose tissue is associated with mortality independently from portal hypertension in patients with cirrhosis	Amine Benmassaoud	Received

THU-497	SARS-CoV-2 infection in patients with underlying chronic liver disease is associated with significantly greater risks of inpatient hospitalization, intensive care unit admission, and overall mortality	Robert Wong	Received

SAT-497	Natural history of Hepatic Encephalopathy (HE) in a tertiary referral centre for hepatology	Chiara Mangini	Received

FRI-498	Association of low mechano-energitic efficiency and prognosis in liver cirrhosis	Sren Mller	Received

THU-498	Low FT3 levels are associated with acute decompensation and acute-on-chronic liver failure	Mona-May Langer	Received

SAT-498	Public knowledge and attitudes toward liver diseases and liver cancer in the brazilian population	Paulo Bittencourt	Received

FRI-499	Long term albumin administration is associated with reduced healthcare resource use in patients with uncomplicated cirrhotic ascites: results from a simulation model	Elisabet Viayna	Received

THU-499	Post hoc analyses of the ATTIRE trial suggest potential gender differences in response to albumin	Alastair OBrien	Received

SAT-499	The negative impact of the pandemic on hospital admissions, morbidity and 30-day mortality for acute cirrhosis decompensation: a tertiary care perspective	Kohilan Gananandan	Received

FRI-500	Improved survival rates in hepatic encephalopathy after a decade of clinical practice with the addition of rifaximin-alpha to lactulose: a real-world data meta-analysis	Juha Halonen	Received

THU-500	Can machines predict liver decompensation? Analysis of 1,415 patients with liver cirrhosis recruited at three German referral centers	Sophie Elisabeth Mller	Received

SAT-500	Comparison of recommended daily energy intakes in people with cirrhosis, based on current guidelines, and their directly measured energy requirements: an individual patient data analysis	Marsha Morgan	Received

SAT-501	Rifaximin for the prevention and treatment of hepatic encephalopathy: a systematic review and meta-analysis of randomized clinical trials	Marsha Morgan	Received

THU-501	LivR Well: a feasibility study for a home-based, multidisciplinary liver optimization program for the first 28 days after an admission for acute-on-chronic liver failure	Natalie Ngu	Received

FRI-501	Risk prediction of hepatic encephalopathy after molecular targeted therapy for hepatocellular carcinoma in patients with cirrhosis	Kisako Fujiwara	Received

FRI-502	ABC: a novel algorithm to stratify decompensation risk in patients with cACLD (CHESS2102): an international, multicenter cohort study	Chuan Liu	Received

SAT-502	Infuence of cirrhotic cardiomyopathy defined according to the new multidisciplinary diagnostic criteria on overall mortality among cirrhotic patients	Simona Bota	Received

THU-502	Alcohol-associated hepatitis with acute-on-chronic liver failure in a diverse cohort: lung and circulatory organ failures along with MELD 35 are predictive of mortality	Stephanie Rutledge	Received

FRI-503	Quantitative parameters of esophageal varices based on computed tomography may be used for predicting severe varices in patients with liver cirrhosis	Shang Wan	Received

THU-503	Bilirubin and its dynamics are independently associated with mortality in patients with acute decompensation of cirrhosis	Konstantin Kazankov	Received

SAT-503	Risk of herpes zoster infection in patients with cirrhosis: a nationwide population-based study in Korea	DONGSUB JEON	Received

THU-504	Impact of predisposition and precipitants on the short-term prognosis among inpatients with chronic liver disease	Yan Zhang	Received

SAT-504	Skeletal muscle pathological fat infiltration (myosteatosis) associates with higher mortality in patients with cirrhosis	Maryam Ebadi	Received

FRI-504	A cost-effectiveness evaluation of the GORE VIATORR TIPS Endoprosthesis versus large volume paracentesis in the management of portal hypertension complications in the Spanish healthcare system	Mitesh Nakum	Received

FRI-505	Factor VIII/protein C ratio does not reflect coagulation but is linked to pathophysiological mechanisms driving disease progression in patients with advanced chronic liver disease	Lorenz Balcar	Received

THU-505	A study evaluating outcomes of a virtual specialist liver cirrhosis clinic	Claudia Moore-Gillon	Received

SAT-505	Application of CT-contrast media is not associated with a higher risk for acute kidney injury in patients with decompensated liver cirrhosis	Tammo Lambert Tergast	Received

SAT-506	Proton pump inhibitors are associated with higher mortality risk and higher risk of decompensation in patients with liver cirrhosis - A retrospective cohort study from the Amsterdam metropolitan area	Koos de Wit	Received

FRI-506	Prognostic impact of variants in TM6SF2 and MBOAT7 in patients who have progressed to advanced chronic liver disease	Lorenz Balcar	Received

THU-506	A novel metabolomics-based prognostic model shows superior diagnostic accuracy than MELD in chronic liver failure	Rudolf E. Stauber	Received

THU-507	Uncovering monocyte transcription, functional and metabolic signatures in recovery and non-recovery ACLF patients	Rita Furtado Feio de Azevedo	Received

FRI-507	Hepatocellular carcinoma and number of elastic bands per session are strong predictors of bleeding after prophylactic endoscopic variceal bleeding	Renato Medas	Received

SAT-507	Maintenance of sarcopenia and myosteatosis after liver transplantation	Franziska Recklies	Received

THU-508	Early initiation of continuous renal replacement therapy improves renal outcomes and survival in patients with acute on chronic liver failure - a prospective cohort study	Rakhi Maiwall	Received

SAT-508	Clinical and prognostic characterization of the patterns of decompensation of liver cirrhosis	Marta Tonon	Received

FRI-508	Simultaneous large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: a randomized controlled trial	Guohong Han	Received

THU-509	Different clinical courses of acutely decompensated cirrhosis in hepatitis B virus high-endemic area: data from Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study	Tongyu Wang	Received

FRI-509	Use of second-harmonic generation microscopy for automated detection of septa and nodules in needle liver biopsies of NASH cirrhosis	Mazen Noureddin	Received

THU-510	Characterization of energy and substrate metabolism in patients with spontaneously breathing and mechanically ventilated patients with liver cirrhosis: an indirect calorimeter based study	Varsha Shasthry	Received

FRI-510	Hepcidin is higher in patients with more severe liver disease independent of portal hypertension	Robin Greinert	Received

SAT-510	Serological assessment of the collagen type III deposition predicts outcome in decompensated liver cirrhosis	Mette Juul Nielsen	Received

THU-511	Extracorporeal membrane oxygenation, a valuable life-saving treatment in liver transplanted patients	Benjamin Buchard	Received

SAT-511	Liver frailty index predicts poor outcomes in patients hospitalized for acute decompensation of cirrhosis	Simone Incicco	Received

FRI-511	Effect of thrombocytopenia and platelet transfusion on outcomes of acute variceal bleeding: a real world experience	Sagnik Biswas	Received

SAT-512	Urinary proteomics identifies oxidative stress and inflammation pathways as key factors differentiating acute-kidney injury-hepatorenal syndrome from acute tubular necrosis in patients with cirrhosis	Laura Napoleone	Received

THU-512	Prevalence, profile and predictors of invasive fungal infections in acute on chronic liver failure (ACLF): analysis of APASL-ACLF research consortium database	Pratibha Ramchandra Kale	Received

FRI-512	Personalized preemptive TIPS treatment for patients with Child-Pugh B cirrhosis and acute variceal bleeding by applying individualized of prediction of treatment effect	Guohong Han	Received

SAT-513	Kidney transplant alone recipients with advanced liver disease have similar outcomes to those without advanced liver disease - a single center study of 150 patients	Rohit Nathani	Received

FRI-513	Real-world survival outcomes in patients with decompensated cirrhosis receiving long term human albumin infusions	Nicholas Hannah	Received

THU-513	Outcomes in patients with cirrhosis and fungal infections: a systematic review and meta-analysis with machine learning	Nipun Verma	Received

SAT-514	Clinical features of exacerbation of portal vein thrombosis after discontinuation of anticoagulants	Takayuki Kondo	Received

THU-514	Impact of de presence of acute on chronic liver failure on morbi - mortality after liver transplantation	Jorge Arnold	Received

FRI-514	Impact of non-ive beta-blockers on survival and liver-related complications after TIPS-Insertion	Anja Tiede	Received

SAT-515	Systemic inflammatory response syndrome and renal resistive index as early predictors of treatment response to terlipressin in hepatorenal syndrome-acute kidney injury	Vijay Narayanan	Received

FRI-516	Derivation of machine learning histologic scores correlating with portal pressures and the development of varices in NASH patients with cirrhosis	Mazen Noureddin	Received

THU-516	Untargeted lipidomics differentiate ACLF precipitated by severe alcoholic hepatitis	florent Artru	Received

THU-517	Metabolomic analysis of organ failure marker compounds in blood samples of patients with decompensated liver cirrhosis after administration of the novel drug VS-01	wenyi gu	Received

SAT-517	Identification of overt hepatic encephalopathy precipitating factors: a pooled analysis of 3 clinical trials of rifaximin plus lactulose	Jasmohan S Bajaj	Received

FRI-517	Ruling out varices needing treatment with a non-invasive score in patients with compensated HBV cirrhosis	Giacomo Emanuele Maria Rizzo	Received

SAT-518	Dementia frequently co-exists with hepatic encephalopathy but not other cirrhosis complications in US veterans with cirrhosis	Adeyinka Adejumo	Received

THU-518	Metabolomic analysis of bacterial infection markers in blood samples of patients with decompensated liver cirrhosis infused with the novel drug VS-01	Olaf Tyc	Received

FRI-518	Evaluation of clinically significant portal hypertension with a novel spleen-dedicated probe using transient elastography	Aitor Odriozola Herrán	Received

THU-519	Disturbances in sodium and chloride hemostasis predict outcome in stable and critically-ill patients with cirrhosis - not two sides of the same coin	Georg Semmler	Received

FRI-519	Are psychometric tests helpful for the prediction of hepatic encephalopathy after TIPS insertion?	Alena Friederike Ehrenbauer	Received

SAT-519	Bacterial infections as a predisposing factor for the development of portal vein thrombosis in cirrhotic patients: a prospective study	Leonardo De Marco	Received